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Dimethyl sulfoxide (DMSO) is a common agent for cryo-preservation despite its known 
toxicity. Dendritic cells (DCs) are potent in antigen uptake when immature, but become 
potent antigen presenting cells (APCs) upon maturation. Macrophages (MFs) are 
professional phagocytes. DMSO primed macrophages and DCs displayed differential 
cytokine production when stimulated with IFN-γ/LPS. DMSO primed DCs showed 
significant up-regulation of IL-12 and down-regulation of IL-10 production upon IFN-
γ/LPS stimulation. IL-23 production by DCs was also up-regulated by DMSO priming. 
Macrophage displayed a more tolerogenic profile and was not as responsive in response 
to DMSO priming unless GM-CSF was used to differentiate macrophages derived from 
monocytes. Cellular viability, morphology, antigen and maturation markers were not 
affected by DMSO priming. This study investigates the regulation of immune responses 
by DMSO primed DCs and how DMSO affects DCs in the cytokine production, 
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CHAPTER 1 INTRODUCTION 
 
1.1 The Immune System – An Overview 
The immune system is a complex defense system that has evolved to protect 
multicellular hosts from pathogenic microorganisms and abnormal cell growth leading 
to cancer. The immune system is able to differentiate between self and invading 
microorganisms. Once identified, the invading microorganisms or pathogens are 
contained, removed or destroyed before any damage could occur to the host. The 
immune system has also been recognized as an important defense mechanism against 
tumour development and cancer leading to the research and development of 
immunotherapy in cancer treatment.  
 
The immune system is built up by a variety of cell types and molecules with distinct but 
unique functional properties. Nevertheless, the cells and molecules are able to act in 
concert to maintain the integrity of the immune system. Cells of the immune system 
originate from their hemapoietic progenitors in the bone marrow. Some cells leave the 
bone marrow after they were created, migrate to other sites such as the thymus and 
mature into effector cells. Many of the immune cells mature in the bone marrow before 
migration to their respective sites in the body where they guard against invading 
pathogens. An immune response is established on two fundamental steps: recognition 
and response. The two events mutually affect each other. The immune system is able to 
detect and recognize a wide variety of foreign pathogens through various receptors. The 
important task therefore is to differentiate these foreign pathogens from the body’s own 
constituents, distinguishing between self and non-self. In doing so, the immune system 
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will then be able to induce appropriate and yet specific immune responses towards the 
specific pathogens.  
 
The immune system in mammals can be classified into two arms: the innate immunity 
and the adaptive immunity (Janeway, 1992). Innate immunity is generally conserved 
across all species but the adaptive immunity is only found in higher vertebrates 
(Medzhitov and Janeway, Jr., 1998). Innate immunity is also known as the natural or 
native immunity, referring to the host’s basic resistance to disease that one is born with 
and is available at the early stages of infection. The innate immune system consists of 
several immunoregulatory components, such as natural killer (NK) cells, phagocytes, 
complements and interferons (IFN) (Fearon and Locksley, 1996). The cells that 
constitute innate immunity express a restricted number of germline-encoded receptors. 
Hence, these cells are able to recognize a wide variety of conserved microbial products 
and pathogens (Janeway and Medzhitov, 2002). Adaptive immunity is referred to as 
‘acquired immunity’ as it is acquired over time through natural microbial encounters or 
vaccination. Adaptive immunity is pathogen specific and possesses immunological 
memory which enables a faster and heightened immune reactivity to the same pathogen 
on its repeated encounter. In other words, adaptive immunity develops as a response to 
infection or vaccination and increases in magnitude and strength with each successive 
exposure to the same microorgamism (Abbas et al., 2000). The main effector cells of 
adaptive immunity are the T cells and B lymphocytes. These cells are capable in highly 
specific antigen detection via a huge repertoire of antigen receptors encoded by somatic 
gene recombination (Fearson and Lockley, 1996). The general properties of both innate 




Table 1.1 Comparison of Innate and Adaptive Immunity 
Properties Innate Immunity Adaptive Immunity 
Effector Cells • NK cells, Monocytes, DCs, 
Macrophages 
• T and B Lymphocytes 
Receptors • encoded in germline 
• no gene rearrangement 
• conserved  
 
• encoded by somatic gene 
recombinations 
• gene rearrangement 




• all class of an identical class 
• clonal 
• all cells of a distinct class 
Recognition • conserved molecular 
patterns 
• specific molecular structures 
Discrimination 
of self vs. non-
self 
• perfect: selected over 
evolutionary time 
• imperfect: selected in 
individual somatic cells 
Time of Action • immediate activation • delayed activation 
Responses • cytokines (IL-1β, IL-6) 
• chemokine (IL-8) 
• co-stimulatory molecules 
• clonal expansion or anergy 
• IL-2 
• effector cytokines (IL-4, IL-
17, IFN-γ) 




While innate immunity and adaptive immunity are considered as two separate events, 
innate immunity and adaptive immunity are closely linked. The activation of innate 
immunity will then provide adaptive immunity with information regarding the nature of 
pathogenic challenge encountered by the host. This cannot be done by the T and B 
lymphocytes although T and B lymphocytes possess great variability in antigen 
recognition. This explains the occurrence of adverse immune response in autoimmune 
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diseases, allergy and allograft rejection. The antigen presenting cells (APCs) of innate 
immunity provide the activating signals through regulation of the surface expression of 
their co-stimulatory molecules such as CD80, CD86 and CD40. Monocytes, 
macrophages and dendritic cells (DCs) constitute the APCs with DCs playing the most 
important role in antigen presentation (Banchereau and Steinman, 1998) as DCs are 
known to be potent activators of T cells. The adaptive immunity will respond and 
enhance the effector mechanisms of innate immunity to efficiently eliminate the 
invading microorganisms. For example, the T cells activated by DCs antigen 
presentation will produce and secrete effector cytokines that will in turn activate 
macrophages and DCs to mount a stronger response towards the invading pathogen. 
Hence, the host is protected from the invading foreign microorganisms via the effective 
interplay of the both arms in the immune system. 
 
1.2 Innate Immunity 
1.2.1 Overview of Innate Immunity 
The innate immunity is known as the front line of host defence against invading 
pathogens. It is an ancient and universal host defence system (Janeway Jr. et al., 2002). 
The innate immune system alone is often sufficient to clear the source of infection 
before a disease develops. The immune mechanisms are able to act immediately because 
they do not require clonal expansion of antigen specific lymphocytes as the adaptive 
immunity does. However, the activation of innate immunity does not lead to 
immunological memory (Janeway Jr., 2002). The other important function of innate 
immunity is to process and present captured antigens for the stimulation of adaptive 
immune responses. The innate immunity relies on a set of germ-line encoded receptors 
to recognize the conserved molecular patterns in specific classes of microorganisms 
5 
 
(Medzhitov, 1998). The advantage of having a non-clonal immune system is that it 
enhances the adaptive immunity by delaying the need of activating adaptive immunity 
while the effector lymphocytes expand and differentiate (Janeway Jr. and Medzhitov, 
2002). 
 
The innate immune system is mainly made up of mechanical, chemical and cellular 
components (Basset et al., 2003). The mechanical components of the innate immunity 
consist of epithelial cells and the mucosal fluid that form a physical barrier to prevent 
entry of infectious pathogens. The chemical components of innate immunity are further 
classified into three subcomponents: (i) fatty acids, proteins, peptides, and enzymes that 
can cause lysis of microbial pathogens; (ii) pattern recognition molecules such as cell 
surface receptors or soluble molecules; and (iii) cytokines and chemokines regulating 
immune responses. Lastly, the cellular components refer to all the cells that play an 
active role in innate immunity. These cells include epithelial cells, eosiniphils, DCs, 
mast cells, phagocytic cells, NK cells and γδ T cells. The natural flora and fauna found 
in the host’s body also form the innate immune system. Together, these components 
identify, contain and remove the invading pathogen. 
 
1.2.2 Myeloid Cells form a Major Arm of Innate Immunity 
The cellular component in innate immunity formed by myeloid cells is a major arm of 
the innate immune system. The generation of immune cells through hematopoiesis is 
divided to lymphopoeisis which generates the lymphocytes and myelopoiesis. Myeloid 
cells include neutrophils, eosinophils, basophils, and monocytes which originate from 





Haematopoietic stem cells produced by the yolk sac migrate to the foetal liver during 
ontogeny and subsequently develop into immature phagocytes (Deimann and Fahimi, 
1978). Monocytes appear in foetal blood ciriculation shortly after haematopoiesis begins 
(Keleman et al., 1979). Monocytes originate in the bone marrow from the committed 
progenitor cells for granulocytes and monocytes. Monocytes share a common myeloid 
progenitor, the colony forming unit granulocyte-monocyte (CFU-GM) with the 
neutrophils (Metcalf, 1971). The progenitor cells differentiate into monoblasts under the 
influence of colony-stimulating factors and then further differentiate into promonocytes, 
which is the first morphologically identifiable cells in this line of differentiation (van 
Furth and Diesselhoff-Den Dulk, 1970). The promonocytes will then divide into two 
daughter monocytes and are released into the blood circulation, circulating in the 
peripheral blood. The mononuclear-phagocyte system and the cells differentiation 
process are illustrated in Figure 1.1 
 
Circulating monocytes migrate into various tissues and differentiate into tissue 
macrophages that possess specific morphological and functional properties according to 
the characteristics of the tissues they reside i.e. alveolar macrophages in the lung, 
microglia cells in the brain and kupffer cells in the liver. Monocytopoiesis can be 
influenced by various growth factors and cytokines. Interleukin 3 (IL-3), granulocyte 
macrophage colony-stimulating factor (M-CSF) and macrophage colony-stimulating 
factor (M-CSF) stimulate the mitotic activity of monocyte precursors (Jones and Millar, 
1989). On the other hand, monocytopoiesis can be suppressed by type-I interferons such 
as IFN-α/β (Perussia et al., 1983) prostaglandin E (PGE) (Pelus et al., 1979) and factor 
increasing monocytopoiesis (FIM) (Metcalf, 1990). Monocytes were reported to be 
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heterogenous and composed of different subsets (Gordon and Taylor, 2005). Monocytes 
were initially identified by their high expression levels of CD14. Differential expression 
of CD14 and CD16 (also known as FCγRIII) provided the current basis for the 




 cells which are 




 cells which resembles mature tissue 
macrophages. It has been shown that monocytes can differentiate into macrophages or 
DCs when cultured in the presence of GM-CSF and interleukin-4 (IL-4) (Sallusto et al., 





 monocyte subset was more likely to differentiate into DCs 





subset remaining in the sub-endothelial matrix developed into macrophages (Randolph 
et al., 1998).  
 




 subset might be precursors of DCs, which can pass 
through tissues and migrate to the lymph nodes through the afferent lymphatic vessels 
































Figure 1.1 The mononuclear-phagocyte system Monocytes differentiate from the 
HSC-GMCFU in bone marrow and can be further differentiated into macrophages, 
dendritic cells, and osteoclast residing in the adult tissues. (Gordon and Taylor, 2005) 
 
1.2.2.2 Monocyte Differentiation 
Monocyte production is greatly increased during inflammation and enters the circulation 
within 24 hours of their formation (van Furth and Sluiter, 1986). Monocytes circulate 
for about 25 hours before extravasation. Monocytes can be activated to differentiate into 
macrophages or DCs upon encountering microbial challenge or infection. GM-CSF and 
M-CSF are both essential in the production of monocytes and macrophages and both 
play an important role in regulating the differentiation of monocytes into macrophages 
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or DCs. GM-CSF and M-CSF can specifically induce the proliferation and 
differentiation of monocytes into distinct subsets of macrophages with various 
morphology and functions. GM-CSF is pivotal in the development of alveolar 
macrophages (Nakata et al., 1991) in the lungs while M-CSF is essential for the 
development of tissue macrophages (Cecchini et al., 1994). The differentiation of 
monocytes into DCs was originally demonstrated in vitro by Sallusto and Lanzevacchia 
in 1994 using monocytes cultured with a combination of GM-CSF and IL-4. Monocyte 
differentiation is now found to be a dynamic process dependent on the tissue or 
secondary organ that monocytes reside (Chen et al., 2009). For example, monocytes 
were able to be differentiated into Th17 immunity polarizing DCs by the blood brain 
barrier secreting transforming growth factor-β (TGF-β) and GM-CSF (Ifergan et al., 
2008). Figure 1.2 shows the monocyte differentiation process.  
 
 
Figure 1.2 Monocyte Differentiation into Macrophage and DCs Figure shows the 
three types of macrophages differentiated from the monocyte precursor under different 




Macrophages are highly phagocytic cells and play an essential role in the maintenance 
of tissue homoestasis through the facilitation of apoptotic cell clearance, destruction of 
invading pathogens and foreign materials, as well as tissue remodeling and repair. 
Macrophages were found to be extremely dynamic as they are able to perform intensive 
membrane trafficking, fusion and fission associated with endocytosis, phagocytosis and 
ruffling (Gordon, 2007). Initially, adult tissue macrophages were thought to be derived 
only from the circulating pool of monocytes. However, later studies indicated that many 
tissue-resident macrophage populations, such as alveolar macrophage (Landsman et al., 
2007), or liver Kupffer cells (Crofton et al., 1978) are maintained through local 
proliferation, especially under steady-state conditions. Inflammation on the other hand 
would result in the massive recruitment of blood-borne precursor of macrophages to the 
respective tissue macrophage compartment (Arnold et al., 2007) but whether these 
tissue macrophages are derived from a particular lineage-committed precursors or 
randomly from the monocyte pool remains elusive. Majority of the macrophages are 
generally considered to be derived from circulating monocytes (Figure 1.3) though 
macrophages do display a high degree of heterogeneity as discovered through various 
studies with monoclonal antibodies (Austyn and Gordon, 1982; Djikstra et al., 1985; 
Kraal and Janse, 1986). Resident macrophages in tissues are also capable of initiating 
acute inflammatory and vascular changes due to their close association with the 
microvasculature in addition to their usual sentinel and clearance functions (Gordon, 
2007). Macrophages display very different turnover rates and poorly defined trophic 
functions. The surrounding environment has been found to dynamically influence the 
phenotype of tissue-resident macrophages (Smythies et al., 2005). For example, isolated 
macrophages from the lamina propria have a unique phenotype of high phagocytic and 
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bacteriacidal activity but weak production of pro-inflammatory cytokines. The 
identification of the diverse macrophage populations found in various organs of the 




Figure 1.3 The ontogeny of Monocyte and Macrophage The development and 




Macrophage being an efficient and dynamic phagocytic cell is able to effectively sense 
the surrounding environment and respond accordingly. That is why macrophages are 
known as the primary danger sensor in the hosts. Macrophages detect endogenous 
danger signals such as those present in necrotic cells through a variety of receptors. The 
common receptors engaged by macrophages in sensing the surrounding signals include 
the Toll-like receptors (TLRs) (Kono and Rock, 2008; Park et al., 2004), intracellular 
pattern-recognition receptors (PPRs) and interleukin-1 (IL-1) receptor which commonly 
signal through myeloid differentiation primary-response gene 88 (MyD88) (Chen et al., 
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2007). The phagocytosis process leads macrophage into dramatic changes in their 
physiology, altering the expression of surface proteins and the production of cytokines 
and inflammatory-mediators (Mosser and Edwards, 2008). These changes serve as 
unique biochemical markers to identify the various types of macrophages. Macrophage 
activation can be due to endogenous stimuli resulted from inflammation or injury.  
Antigen-specific immune cell present will generate signals that are specific and 
prolonged to give rise to longer-term alteration in macrophages. In addition, 
macrophage themselves can produce alterations and signals that result in changes of 
their own physiology. Activated macrophages can be generally classified into three 
different populations with each population possessing unique physiological properties; 
(i) the classically activated macrophages, (ii) wound-healing macrophages and (iii) 
regulatory macrophages. The unique physiological properties of the three macrophages 
populations provide a series of unique biomarkers that may be useful for disease 
identification (Mosser and Edwards, 2008).  
 
(i) Classically activated macrophages 
Classically activated macrophages traditionally refer to macrophages that are activated 
by the production and release of interferon-γ (IFN-γ) and tumour-necrosis factor-α 
(TNF-α). These macrophages in turn secrete high amounts of pro-inflammatory 
cytokines or mediators and display enhanced microbicidal and tumouricidal activity 
(O’Shea and Murray, 2008). Hence, classically activated macrophages refer to 
macrophages that are produced under cell mediated immunity. Besides IFN-γ and TNF-
α, other cytokines such as IFN-α/β are also able to activate macrophages. NK cells and 
T cells are the main contributors to the production of these cytokines. TLRs were shown 
to be important in the generation of classically activated macrophages involving the 
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activation of signal transducer and activator of transcription (STAT) pathway and the 
nuclear factor-κB (NF-κB) pathway (O’Shea and Murray, 2008). 
 
Classically activated macrophages therefore play an important role in protecting the host 
against invading pathogens as the pro-inflammatory cytokines produced would result in 
the killing and elimination of the invading pathogens. Mice deficient in IFN-γ 
production were found to be more susceptible to bacterial infection (Felipe-Santos et. 
a.l., 2006). However, the pro-inflammatory cytokines can also contribute to serious 
tissue and host damage such as autoimmunity if not properly regulated (Langrish et al., 
2005). Hence, though classically activated macrophages are important in host defence, 
their activity must be tightly controlled to prevent unnecessary damage to the host.  
 
(ii) Wound-healing macrophages 
Wound-healing macrophages as the name suggests refer to macrophages that are 
generate for the purpose of tissue repair. Initially, these macrophages were referred to as 
‘alternative macrophages’ as these macrophages respond efficiently to the mannose 
receptor (Stein et al., 1992) and were important in the clearance of helminthes and 
nematodes (Anthony et al., 2006; Zhao et al., 2008). Wound healing macrophages are 
usually generated in response to the production of interleukin-4 (IL-4) during tissue 
injury (Loke et al., 2007). The main contributors to the production of IL-4 during tissue 
injury are the granulocytes especially basophils and mast cells. In vitro studies showed 
that macrophages treated with interleukin-4 (IL-4) or interleukin-13 (IL-13) produced 
less pro-inflammaotry cytokines, displayed less bactericidal activity, had lesser 
production of oxygen and nitrogen radical species (Edwards et al., 2006) but were able 
to produce components of the extracellular matrix, suggesting that these macrophages 
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were involved in wound healing and tissue repair. Wound-healing macrophages too can 
be a threat to the host when the matrix-enhancing ability is not efficiently regulated. 
Experimental studies have suggested that the over-expression of extracellular matrix 
components due to uncontrolled activation of these macrophages can lead to formation 
of tissue fibrosis (Hesse et al., 2001) and airway remodeling (Munitz et al,. 2008). 
 
(iii) Regulatory macrophages 
Regulatory macrophages were found to have reduced inflammatory response by 
decreasing the transcription of pro-inflammatory cytokines genes and decreasing 
messenger ribonucleic acid (mRNA) stability (Stenberg, 2006). Glucocorticoids 
released by adrenal glands in response to stress are one of the main factors mediating 
the generation of regulatory macrophages by affecting macrophage functions (Elenkov, 
2004). Another important role of regulatory macrophages is to dampen the immune 
response and limit the degree of inflammation at later stages of adaptive immune 
response. This is to ensure that there will be no over-activation of the adaptive immune 
response which would cause detrimental effects to the host (Mosser, 2003). 
Macrophages itself can also produce the regulatory cytokine TGF-β after phagocytosis 
of apoptotic cells to induce the immunoregulatory functions of macrophages (Fadok et 
al., 1998).  Studies by (Mosser and Edwards) first identified a population of 
macrophages that displayed regulatory properties through in vitro stimulation of 
macrophages with TLR agonists in the presence of immunoglobulin-G (IgG) immune 
complexes (Gerber and Mosser, 2001). In their studies, the macrophages were found to 
be potent producers of the immunosuppressive cytokine interleukin-10 (IL-10). Though 
there are many different ways in which regulatory macrophages are generated, the exact 
mechanism mediating the transformation of macrophages into a regulatory phenotype 
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remains unknown. Both mitogen-activated protein kinase (MAPK) and extracellular-
signal-regulated kinase (ERK) have been suggested as potential candidates in the 
generation of regulatory macrophages (Gerber and Mosser, 2001).The characteristics of 
regulatory macrophages may differ slightly depending on the stimuli that led to their 
generation. Nevertheless, the regulatory macrophages are still identifiable by a few 
common properties. Regulatory macrophages are potent IL-10 producers and are 
capable of suppressing the production of pro-inflammatory cytokines such as 
interleukin-12 (IL-12) (Gerber and Mosser, 2001). Regulatory macrophages also do not 
produce any extracellular matrix protein but expresses high levels of co-stimulatory 
molecules such as CD80 and CD86. Therefore, regulatory macrophages do contribute to 
T cell activation through antigen presentation (Edwards et al., 2006). Many parasitic, 
bacterial and viral pathogens make use of the immunosuppressive properties of 
regulatory macrophages to evade host detection and killing (Miles et al., 2005; 
Baetselier et al., 2001) 
 
The three different populations of macrophage showed that macrophage physiology can 
be influenced by various innate and adaptive immune signals (Stout et al., 2005) as 
shown in Figure 1.4. The plasticity of macrophages has made it difficult to identify and 
classify them through a single biochemical marker. The plasticity of macrophages can 
also be observed from their response to diseases in the hosts. Macrophages are thought 
to play an important role in the eradication of tumour cells due to its phogocytic ability. 
Classically activated macrophages were shown to be cytotoxic to cancer cells (Romieu-
Mourez et al., 2006). However, tumour associated macrophages were found to have 
switched to a phenotype similar to regulatory macrophages due to the influence of the 
tumour microenvironment as the tumour progresses (Pollard, 2008). Macrophages were 
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found to also play an important role in the development of insulin resistance associated 
with obesity. Studies showed that obese individuals have macrophages accumulated in 
their adipose tissues. These adipose-associated-macrophages can therefore be a source 
of pro-inflammatory cytokines and over time lead to the development of insulin 
resistance and ultimately type two diabetes (Zeyda and Stulnig, 2007; Lument et al., 
2007). The heterogeneity of macrophages remains a mystery but is important as it 
enables macrophages to play important roles in host immunity through regulation of 















Figure 1.4 Factors regulating the activation of various macrophages Macrophage 
respond and activate into three different classes of macrophages according to 




1.2.2.4 Dendritic Cells 
Dendritic cells were first observed by Paul Langerhans in 1868 as he mistakenly 
classified the stellate-shaped epidermal cells as cutaneous nerve cells (Langerhans, 
1868). A century later, Steinman and Cohn discovered dendritic cells in mouse spleen 
and named them ‘dendritic cells’ based on the unique morphology of DCs when they 
observed these cells (Steinman and Cohn, 1973). Currently, it is widely accepted that 
DCs arise from haemapoietic precursors in the bone and are ubiquitously distributed in 
lymphoid and non-lymphoid tissues. DCs are now regarded as representing a discrete 
leukocyte population which are highly specialized in antigen presentation and possess 
the unique ability to activate primary immune response (Hart, 1997; Steinman, 1991). 
Hence, DCs are known to be the professional antigen presenting cells (APCs). 
Extensive studies to date have revealed that DCs are not just critical APCs for the 
induction of primary immune responses and the regulation of T cell-mediated immune 
response (Liu, 2001; Shortman and Liu, 2002; and Banchereau et al., 2001). DCs also 
serve as sentinels by recognizing the invading pathogens through the various pattern-
recognition receptors (PPRs). DCs activated by microbial products secrete pro-
inflammatory cytokines involved in host defense, providing a crucial link between 
innate and adaptive immunity (Rescigno and Borrow, 2001; Iwasaki and Medzhitov, 
2004).  
 
DC ontogeny has been divided into four stages, (i) bone marrow progenitors, (ii) 
circulating DC precursors, (iii) tissue-residing immature DCs (imDCs), and (iv) mature 
DCs (mDCs) in secondary lymphoid organs (Shortman and Naik, 2006). DCs 
precursors from haemapoietic progenitors in the bone marrow circulate through the 
blood and lymphatics to their respective tissues. DCs reside in these tissues as immature 
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cells possessing potent phagocytic capacity, which is a characteristic of imDCs. Upon 
encountering infection or tissue damage, imDCs will capture and process antigen such 
as microbial product lipopolysaccharide (LPS), and migrate to the lymphoid organs. The 
imDCs will then mature into mDCS and present the captured antigen to the antigen-
specific T cells, activating the host immune response. Hence, DCs are critical to the 
induction of adaptive immunity as DCs are required to activate naïve T cells to induce a 
primary immune response and establish immunological memory (Banchereau and 
Steinman, 1998). In other words, DCs are important in the induction and maintenance of 
both central and peripheral tolerance (Steinman et al., 2003; Lutz and Schuler, 2002). 
The diverse functions of DCs in immune regulation reflect the heterogeneity of DC 
subsets and functional plasticity. 
 
1.2.2.5 Heterogeneity of dendritic cell subsets 
DCs in lymphoid organs have been widely considered as the end stage of a stepwise 
differentiation and migration process during inflammation to initiate immune responses 
(Fearson and Locksley, 1996; Lanzavecchia, 1996). There are no DC lineage-specific 





 cells in combination with various cell surface markers (Sato 
and Fujita, 2007). Most of the knowledge about the developmental pathway of DCs was 
based on results obtained by cell culture studies. Cells with characteristics of 
Langerhans cells and DCs can be generated in vitro by culturing CD34
+
 cells in the 
presence of GM-CSF and TNF-α (Caux et al., 1996).  
 
imDCs are continuously produced from hemapoietic stem cells within the bone marrow. 
Human DCs are defined by lineage-MHC II
+
 cells and all express CD4 but lack CD8 
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expression (Sato and Fujita, 2007). DC heterogeneity in humans is reflected at four 
levels; (i) precursor populations, (ii) anatomical localization such as skin epidermal 
Langerhans cells, dermal (interstitial) DCs, splenic marginal DCs T-zone interdigitating 
cells, germinal-centre DCs, thymic DCs, liver DCs, and blood DCs, (iii) function and 
(iv) final outcome of immune resonse i.e. tolerance vs. immunity (Banchereau et al., 
2000). CD34
+
 hemapoietic stem cells differentiate into two different progenitors; the 
common lymphoid progenitor (CLP) and the common myeloid progenitor (CMP). The 









 cells and 
subsequently migrate into the skin epidermis to differentiate into Langerhans DCs. CLA 














 DCs will further differentiate into interstitial DCs (Strunk et al., 1997; Ito 
et al., 1999). Langerhans DCs and interstitial DCs are very different phenotypically and 
functionally though both originate from the same precursor. Langerhans DCs have high 
expression levels of CD1a, Birbeck Granule and E-cadherin while interstitial DCs 
express CD2, CD9, CD68 and factor XIIIa. Functionally, Langerhans DCS are potent in 
CD8 T cell-priming but are not capable of macropinocytosis; interstitial DCs on the 
other hand are capable of macropinocytosis and the activating T and B cells. Table 1.2A 
summarizes the differences between Langerhans DCs and interstitial DCs.  
 
Another two types of DC precursors (pre-DC) can be obtained from CMP and CLP 
respectively in the bone marrow. CMP give rise to myeloid pre-DC1s which are also 
known as monocytes while CLP give rise to lymphoid pre-DC2s (plasmacytoid DCs) 
(Liu, 2001). Monocytes migrate to the blood and then to extravascular tissues before 
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differentiating into myeloid DCs (DC1). On the other hand, plasmacytoid DCs would 
migrate into the blood and then to the lymphoid tissues. The differences between DC1 
and DC2 are summarized in Table 1.2B. These conventional DC subsets can elicit either 
Th1- or Th2- immune responses depending on the inflammatory environments (Wang et 
al., 2006; Ito et al., 2004; Ito et al., 2007). Figure 1.5 shows the development of the DC 
subsets. Recent studies also indicate that bone marrow plasmacytoid DCs are able to 
differentiate into myeloid DCs upon viral infection (Zuniga et al., 2004). Similar to 







































Figure 1.5 The development, differentiation and maturation process of DCs. DCs 
originate from CD34+ hemapoietic stem cells that differentiate into CMPs and CLPs. 
CMPs further differentiate into CD34+CLA+ and CD34+CLA- progenitor cells which 
would differentiate Langerhans DCs and interstitial DCs respectively. CMP and CLP 
also give rise to monocyte/pre-DC1 and plasmacytoid / pre-DC2 which would result in 
myeloid DCs and plasmacytoid DCs that migrate into the blood and then into lymphoid 






Table 1.2 Comparison of DC subsets 
A. Comparison of Langerhans Cells and Interstitial DCs 
 Langerhans Cells Interstitial DCs 
Phenotype   
CD1a + - 
CD2 - + 
CD9 - + 
CD68 - + 
Factor XIIIa - + 
E-cadherin + - 
Birbeck Granule / Lag-antigen + - 
Function   
Macropinocytosis - + 
IL-10 production - + 
B cell activation +/- + 
CD8 T Cell priming +++ + 
 
B. Comparison between pre-DC1 and pre-DC2 
 Pre-DC1 Pre-DC2 
Phenotype   
Myeloid marker   
CD11b + - 
CD11c + - 
CD13 + - 
CD14 + - 
CD33 + - 
Lymphoid Marker   
Pre-Tα - + 
Ig γ-like 14.1 - + 
Spi-B - + 
Pattern recognition receptors   
Mannose R +/- - 
CD1a, b, c d +/- - 
Other differentially expressed antigen   
CD4 + ++ 
CD45RA - + 
CD45RO + - 
IL-3R + +++ 
GM-CSF ++ + 
Function   
Phagocytosis and kill bacteria ++ - 





C. Comparison of CD11c
+




Phenotype   
Dendrites or veils + - 
Co-stimulatory molecules Moderate Low 
Mobility High Low 
Colonization of non-lymphoid 
tissues without stimulation 
Yes No 
Function   
T cell activation Moderate No 
Innate Immunity Low High 
   Tables with modifications from Liu, 2001 
 
1.2.2.6 Dendritic cell maturation and migration 
The mobility of DCs at various differentiation stages is a unique and important 
characteristic that enabled DCs to function effectively. DC maturation is a pivotal event 
and provides a crucial control of innate and adaptive immunity. DCs migrate from bone 
marrow to the peripheral tissues, encountering antigens that would trigger their 
maturation and migration to the secondary lymphoid organs. The antigen or pathogen 
encountered induces the imDCs to undergo phenotypic and functional changes that 
result in the transition of imDCs from antigen-capturing cell to APC. DC maturation 
and DC migration are two closely intertwined events that would affect the outcome of 
immune response. Defects in DC maturation have been linked to the progression of 
cancer (Lin et al., 2009). 
 
DC maturation is a continuous process that is initiated in the periphery upon antigen 
encounter and / or inflammatory cytokines leading to DC-T cell interaction as the final 
point (Banchereau et al., 2000).  DC maturation can be induced and regulated by a 
series of exogenous and endogenous factors as shown in Figure 1.6: (i) pathogen-related 
molecules such as LPS, lipotechoic acid (LTA), peptidoglycan (PGN), flagellin, 
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bacterial deoxyribonucleic acid (DNA) and double-stranded DNA; (ii) the balance 
between pro-inflammatory and anti-inflammatory signals in the local microenvironment, 
such as TNF, IL-1, IL-6, IL-10, TGF-β and prostaglandins; (iii) T cell-derived signals 
such as TNF-α, CD40L and IFN-γ; and (iv) tissue damage-derived signals i.e. heat-
shock proteins (Banchereau et al., 2000; Rossi and Young 2005). DC maturation is a 
process that requires several coordinated events such as (i) loss of endocytic / 
phagocytic receptors; (ii) up-regulation of co-stimulatory molecules CD40, CD58, 
CD80 and CD86; (iii) morphological changes such as loss of adhesive structure, 
cytoskeleton reorganization, and acquisition of high cellular motility (Winzler et al., 
1997); (iv) a shift in lysosomal compartments with down-regulation of DC-lysosome-
associated membrane protein (DC-LAMP); and (v) change in Major Histocompatibility 
Complex class II (MHC II) compartments (Banchereau et al., 2000). Upon encountering 
antigen / pathogen, imDCs are activated to become mDCs by down-regulating cell 
surface expression of endocytic / phagocytic receptors while up-regulating the 
expression of co-stimulatory molecules as mentioned to facilitate the migration and 
subsequently interaction of mDCs with T cells. CD83 is another cell surface marker that 
is often used to mark DC maturation in humans. However, the exact function of CD83 is 
still not clear (Zhou and Tedder, 1996).  
 
The process of DC maturation is closely linked to and followed by DC migration. 
Mediators of DC maturation will also trigger peripheral DC migration into the T cell 
area of lymphoid organs to facilitate antigen presentation by DCs and subsequently T 
cell activation for immune response. DC migration too requires a series of coordination 
between several chemokines. imDCs lose their responsiveness towards chemokines 
specific for imDCs such as MIP-3α through either receptor down-regulation of 
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desensitization upon antigen uptake (Dieu et al., 1998; Sallusto et al., 1998). imDCs 
down-regulate the expression of chemokine receptors CCR1, CCR5 and CCR7 
responsible  for recognizing inflammatory cytokines. imDCs also up-regulate the 
expression of CCR7 receptor which recognizes lymphocyte chemokines (Sozzani et al., 
1999). mDCs acquire responsiveness to chemokines of lymphoid tissues, enter into the 
draining lymph nodes and migrate to the T cell zone (Ngo et al., 1998). These series of 
well-coordinated events (Figure 1.6) will hence lead to the complete functional 

















Figure 1.6 DC Maturation The left side of the diagram shows the factors regulating 
DC maturation while the right side of the diagrams summarizes the properties of each 
maturation stage. (Banchereau et al., 2000). 
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1.2.2.7 DCs in antigen uptake, processing and presentation  
DCs are known to be the professional APCs. DCs are well equipped to capture and 
process antigens into proteolytic peptides, load these peptides onto MHC molecules and 
present them to T cells. imDCs can efficiently internalized a diverse array of antigens 
for processing and are characterized by high levels of endocytic activity which is lost 
upon maturation. Immature DCs internalize Ag through multiple pathways. Many 
receptors contribute to the ability of DCs to capture exogenous antigens (Marina et al., 
1997). The common receptors identified so far include mannose receptor; C-type lectins 
such as DEC-205 (Jiang et al., 1995) and CD23 (Mudde et al., 1990); FcεRI (Maurer et 
al., 1995; Bieber et al., 1992); Fcγ receptor type I and II (Fanger et al., 1996); 
complement receptor 3 and 4 (Reis de Sousa et al., 1993), and Scavenger receptors 
(Platt et al., 1998). These receptors help DCs in antigen uptake by facilitating receptor-
mediated endocytosis, allowing the uptake of macromolecules through specialized 
regions of the plasma membrane, known as coated pits. The same receptors mediating 
endocytosis also mediates the internalization of particulate antigens. The process of the 
uptake of particulate antigens is referred to as phagocytosis. Phagocytosis is actin 
dependent as it requires membrane ruffling and the subsequent formation of large 
intracellular vacuoles. Immature DCs have been reported to be able to engulf almost any 
bacteria (Bell et al., 1999) and phagocytose apoptotic and necrotic bodies (Albert et al., 
1998). Studies with monocyte derived DCs generated from culture with GM-CSF and 
IL-4 showed that these DCs have high level of constitutive macropinocytosis allowing 
them to take up large volumes of fluid and concentrate the macrosolutes (Sallusto et al., 
1995). This enables imDCs to continuously sample the microenvironment in a rapid and 
non-specific manner. Macropinocytosis requires the engulfment of large amount of fluid 
and solutes by the DCs and hence involves actin rearrangement. 
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DCs process captured antigens into proteolytic peptides and target these peptides to 
MHC class I (MHC I) and MHC class II (MHC II) molecules. The peptide loading for 
antigen presentation can be achieved in three ways; (i) MHC II-restricted pathway; (ii) 
MHC I-restricted pathway; and (iii) CD1-restricted pathway. 
 
(i) MHC II-restricted pathway 
Immature DCs constantly accumulate MHC II molecules in lysosome-related 
intracellular compartments identified as MHC class II-rich compartments (MIICs) with 
multivesicular and multilamelar structures (Klejimeer et al., 1995; Nijman et al., 1995). 
Exogenous antigen captured by DCs are degraded in endosomes and directed towards 
MIIC containing HLA-DM that promotes the catalytic removal of the class II-associated 
invariant chain peptide. The invariant chain also enhances peptide binding to MHC II 
molecules (Cresswell, 1996; Castellino et al., 1997) although loading of class II antigens 
within DC can also occur in the absence of the invariant chain (Rovere et al., 1998). The 
invariant chain is degraded upon DC maturation and the peptide-loaded class II 
molecules will be exported to the cell surface for presentation (Pierre and Mellman, 
1998).  
 
(ii) MHC I-restricted pathway 
The MHC I pathway can be loaded with antigen through both an endogenous and an 
exogenous pathway for DC presentation to generate CD8+ cytotoxic killer cells (Pamer 
and Cresswell, 1998; Rock and Goldberg, 1999). The endogenous pathway involves the 
degradation of cytosolic proteins within the endoplasmic reticulum where the peptides 
will be loaded onto newly synthesized MHC I molecules. The ATP-dependent 
proteolytic system processes the antigen by ubiquitin conjugation (Guermonprez et al., 
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2002). The ubiquitinylated proteins are then directed to the proteasome, in which the 
proteins are cleaved into peptides and translocated via the endoplasmic reticulum onto 
the ATP-dependent transport associated-protein 1 / 2 (TAP 1/2) transmembrane 
transporters, fitting them into the MHC class I-binding groove. Minor antigens, 
exogenous peptides generated from phagocytosed particulated antigens, viruses, or 
immune complexes can also be presented by MHC I molecules (Norbury et al., 1997; 
Shen et al., 1997). This process is termed cross priming. Two pathways have been 
identified to facilitate cross presentation of antigens on DCs. The first pathway is a 
TAP-independent pathway is which the antigens are most likely hydrolyzed in 
endosomes (Pfeifer et al., 1993) while the second pathway is a TAP dependent 
phagosome-to-cytosol pathway (Kovacsovics-Bankowski et al., 1993; Kovacsovics-
Bankowski et al., 1995).  
 
(iii) CD1 molecules-restricted pathway 
The CD1 family of molecules has been identified as non-classical, Ag-presenting 
molecules involved in the regulation of T cell responses to both microbial lipids and 
glycolipids-containing Ag (Burdin and Kronengerg, 1999; Porcelli and Modlin, 1999). 
CD1 molecules are a hallmark of DC phenotype and facilitate antigen presentation in a 
TAP-independent manner. Four CD1 proteins (CD1a-d) are expressed by myeloid DCs 
in humans. CD1 proteins are functionally heterogenous and can present glycolipids to a 
large repertoire of T cell, as well as natural killer (NK) T cells (Kitamura et al., 1999). 
The CD1-restricted pathway contributes not only to the microbial immunity but to 
autoimmunity and antitumour response. CD1-restricted antigen presentation also 




1.2.2.8 In vitro human DC differentiation models – monocyte derived DCs 
The study of DC differentiation in vitro has gathered a lot of attention over the years as 
influenced by the objective of optimizing DC culture system for use in cancer 
immunotherapy. Currently, the two main protocols established to generate DCs in vitro 
uses either monocytes (Sallusto and Lanzavecchia, 1994) or CD34
+
 precursors (Caux et 
al., 1994) as a source. 
 
Peripheral blood mononuclear cells (PBMC) are isolated from blood or buffy coat 
preparations through density gradient centrifugation. Upon obtaining the PBMCs, 
monocytes can be further separated from the lymphocytes with various methods. One of 
the most common methods is the adhesion method, where monocytes are allowed to 
adhere to a plastic surface (Bennet and Breit, 1994). This method is preferred by many 
because it is inexpensive and relatively easy to perform. However, the yield and purity 
of the monocytes obtained can vary greatly. Other methods include immunoselection, 
such as magnetic cell sorting and centrifugal elutriation. These two methods are much 
more expensive and requires extensive equipment and expertise to be carried out 
successfully and hence, less popular for frequent isolation. 
 
The isolated monocytes can be differentiated into imDCs by GM-CSF and IL-4. The 
DCs generated (monocyte-derived DCs) have typical dendritic morphology, with 
obvious dendrite projections, express high levels of MHC I, MHC II, CD1, FCγ 
receptors, CD40, B7, CD44, and ICAM-1 but not CD14. These cultured DCs are highly 
capable of stimulating T cells in a mixed leukocyte reaction (MLR) and are also able to 
trigger cord blood naïve T cells as they are potent in IL-12p70 production and other 
inflammatory cytokines (Granucci et al., 2001). Monocyte derived DCs can be driven 
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into a mature state by treating the cells with maturation mediators such as LPS, TNF-α, 
interferon-gamma (IFN-γ) or CD40L. These resulting mature DCs may differ slightly 
morphologically and functionally (Timmerman and Levy, 1999).  
 
1.2.3 Pattern Recognition Receptors 
Pathogen recognition by the innate immune system is dependent on the pattern 
recognition receptors (PRRs) that recognize conserved molecular patterns on different 
microbial classes to determine the type of infection agent encountered (Medzhitov et al., 
2000) so as to mount an appropriate immune response against the pathogen. Cells of 
innate immunity that express PRRs are macrophages, dendritic cells, mast cells, 
neutrophils, eosinophils, and NK cells (Janeway and Medzhitov, 2002). These 
conserved molecular patterns are mostly products of metabolic pathways or gene 
products that are essential for the survival of the microorganism and are termed 
pathogen-associated molecular patterns (PAMPs). The PRRs can be expressed on the 
cell surface, in intracellular compartments, or secreted into the bloodstream and tissue 
fluids. (Medzhitov and Janeway, 1997). PRRs can be classified into two major groups 
(Aderem and Underhill, 1999; Janeway and Medzhitov, 1998). The first group is the 
sensing receptors which can distinguish between different pathogens leading to the 
activation of pro-inflammatory pathways. This group consists mainly of the Toll-like 
receptors (TLRs). The second group of PRRs forms the mechanical arm of innate 
immunity is made up by the phagocytic and endocytic receptors, such as mannose 
receptor (MR), scavenger receptor (SR), and complement receptor (CR). The PRRs can 
therefore function in (i) opsonization of bacteria and viruses for complement activation 
(Fraser et al., 1998); (ii) pathogen uptake by phagocytes and dendritic cells for antigen 
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presentation (Stahl and Ezekowitz, 1998); or (iii) cell signaling to induce antimicrobial 
peptides and inflammatory cytokines and induction of apoptosis. 
 
In addition to the two main groups of PRRs which are found on the cell surface, there 
are also several secreted PRRs such as surfactant protein A (SP-A) and D (SP-D), the 
mannose lectin (MBL) (Lu et al., 2002), C-reactive protein (CRP), serum amyloid 
protein (SAP) (Schwalbe et al., 1992), LPS-binding protein (LBP) and CD14. Some 
other PRRs are expressed in the cytosol where they function in detecting intracellular 
pathogens and induce immune responses that block pathogen replication. Examples of 
such PRRs are protein kinase receptor (PKR) (Clemens and Elia, 1997), nucleotide-
binding oligomerization domain (NOD) proteins (Hammond-Kosack and Jones, 1997) 
and 2’-5’-oligoadenylate synthase (OSA) (Kumar and Carmichael, 1998).  
 
1.2.3.1 Phagocytic Receptors 
Phagocytosis refers to the process by which phagocytic cells internalize large particles. 
Phagocytosis is an important component of host innate immunity and is often referred to 
as the classic model of microbe-innate immune cell interaction (Stossel, 1999). 
Phagocytes rely on phagocytic receptors for the uptake of microbial antigens which are 
degraded in APCs into antigenic epitopes for MHC molecules. These epitopes dictates 
the specificity of mounting responses. Phagocytosis is accompanied by intracellular 
signals that trigger various cellular processes such as cytoskeletal rearrangement, 
alterations in membrane trafficking, activation of microbial killing mechanisms, 
production of pro-inflammatory and anti-inflammatory cytokines and chemokines, 
induction of apoptosis, and production of molecules required for effective antigen 
presentation to activate the adaptive immunity (Underhill et al., 1999). There are a 
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variety of receptors that constitute this arm of host immunity (Figure 1.7). Phagocytes, 
such as macrophages and DCs express a broad spectrum of receptors to bind and 
internalize microbes (Underhill and Ozinsky, 2002). The mannose binding receptor 
(Fraser et al., 1998; Stahl and Ezekowitz, 1998) recognizes mannose residues on 
microorganisms. The Fc receptors (Gerber and Mosser, 2001; Heyman, 2000) 
phagocytose signaling receptors that down-regulate the production of pro-inflammatory 
cytokines and enhance T helper two (Th2)- mediated immune response (Radstake et al., 
2004; Sutterwala et al., 1998) through the ligation of Fc receptors. The complement 
receptors (Gasque, 2004) bind to complement-opsonized pathogens to facilitate 
phagocytosis. Table 1.3 summarizes the phagocytic receptors and their ligands. 
 
Figure 1.7 Receptor and signaling interactions during phagocytosis. Multiple 
receptors act in concert to recognize microbes through direct binding of binding to 
opsonized proteins. The engagements of these receptors result in the activation of 
various downstream signaling pathways, resulting in a specific immune response. 
(Underhill and Ozinsky, 2002). 
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Table 1.3 Phagocytic receptors for microbes 
Receptors Ligands 
Fc Receptors: 
  FcγRI (CD64) IgG-, CRP-, SAP-opsonized particles 
  FcγRII (CD32) IgG-, CRP-, SAP-opsonized particles 
  FcγRIII (CD16) IgG-, CRP-, SAP-opsonized particles 
  FcεRI IgE-opsonized particles 
  FcεRII (CD23) IgE-opsonized particles 
  FcεRIIII (CD89) IgA-opsonized particles 
Complement Receptors: 
  CR1 (CD35) MBL-, C1q-, C4b-, C3b-opsonized particles 
  CR3 (αMβ2, CD11b/CD18, Mac1) iC3B-opsonized particles 
  CR4 (αXβ2, CD11c/CD18, gp150/95) iC3B-opsonized particles 
Integrins: 
  α5β1 (CD49e/CD29) Fibronectin/Vitronectin-opsonized particles 
  α4β1 (CD49d/CD29)  
  αvβ3 (CD51CD61)  
Scavenger Receptors: 
  SRA Bacteria, LPS, LTA 
  MARCO Bacteria  
Mannose Receptor (CD206) Mannan 
Dectin-1 Β1,3-glucan 
CD14 LPS, peptidoglycan 
C1qR(P) C1q, MBL, SP-A 




1.2.3.2 Toll-like Receptors (TLRs) 
The Toll receptor was first identified in the developing embryo of Drosophila as an 
essential receptor and was found to be involved in anti-fungal responses in the adult fly 
(Imler and Hoffman, 2001). Subsequent discoveries led to the identification of Toll 
receptors in mammals and the important roles Toll receptors play in the recognition of 
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microorganisms. The first mammalian homologue of the Toll receptor was identified in 
1997 and named hToll (now TLR4) (Medzhitov et al., 1997). Several TLR4 structurally 
related proteins were identified through various studies leading to the identification of 
the panel of Toll-like receptors (TLRs). There are altogether 12 members in the TLR 
family identified so far in mammals (Janeway and Medzhitov, 2002; Akira et al., 2006; 
Medzhitov, 2007; Beutler, 2009). The human TLR family consists of 10 members 
(TLR1 to TLR10) while twelve TLRs family members were identified in mice.  
 
TLRs are type I integral membrane glycoproteins and possess a trimodular structure 
(Kumar et al., 2009). The cytoplasmic portion which is the intracellular C-terminal 
domain of TLRs displays high similarity to the IL-1 receptor family, known as the 
Toll/IL-1 receptor (TIR) domain. This domain is required for the interaction and 
recruitment of various adaptor proteins to activate the downstream signaling cascade for 
TLRs. The extracellular domains of both receptors however, were structurally unrelated. 
The extracellular N-terminal domain of TLRs bears approximately 16-28 leucine-rich 
repeats (LRRs), with each LRR comprising of 20-30 amino acids with the conserved 
motif “LxxLxLxxN” (Janeway and Medzhitov, 2002; Akira et al., 2006; Medzhitov, 
2007; Beutler, 2009). The crystal structure of the TLRs and their ligand complex has 
been revealed recently (Jin et al., 2008) showing that these complexes can form 
heterodimers (TLR1-TLR2 or TLR4-MD2) (Jin et al., 2007; Kim et al., 2007) or 
homodimers (TLR3-TLR3) after association with their respective agonist or antagonist 
ligands. The complex will then assume a horseshoe-like structure (m-shape) which is 





A comparison of the amino acid sequences of the human TLRs divided the human TLRs 
into five groups: The TLR3, TLR4, TLR5, TLR2 and TLR9 subfamilies (Gangloff et al., 
2003; Takeda et al., 2003). The TLR2 subfamily members are composed of TLR1, 
TLR2, TLR6 and TLR10, while the TLR9 subfamily comprises of TLR7, TLR8 and 
TLR9. These TLRs are expressed in distinct cellular compartments aiding in the 
effective recognition of various PAMPs by TLRs. TLR1, TLR2, TLR4, TLR5, and 
TLR6 are expressed on the cell surface whereas TLR3, TLR7, TLR8 and TLR9 and 
expressed in intracellular vesicles such as the endosome and ER. The intracellular TLRs 
are transported to the intracellular vesicles via the transmembrane protein localized in 
the endoplasmic reticulum (Kim et al., 2008; Brinkmann et al., 2007). 
 
1.2.3.2.1 TLRs and their ligands 
TLRs can recognize various PAMPs from bacteria, viruses, fungi, protozoa, making 
them the most important sensing receptors for the activation of immunity. TLRs are also 
able to recognize non-PAMPs endogenous ligands such as heat-shock proteins and 
extracellular matrix degradation products (Takeda et al., 2003). The TLRs ligands were 
mostly identified through in vitro studies using ligand binding assays or through in vivo 
generation of knockout mice. Table 1.4 provides a detailed summary of the TLRs with 
their ligands and the signaling pathways involved. 
 
TLR1 
TLR1 was discovered to be functionally associated with TLR2 through co-expression 
studies of TLR1 and TLR2 in HeLa cells by Wyllie et al., 2000. The co-transfected 
HeLa cells exhibited responsiveness to soluble factors released from Neisseria 
meningitides. Studies using TLR1-deficient mice demonstrated that TLR1 is involved in 
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the recognition of triacyl lipopetides which is mainly found on bacteria and 
mycobacteria (Takeuchi et al., 2002). TLR1 has also been shown to be involved in the 




TLR2 can recognize components from a variety of microbial pathogens including 
lipoproteins from gram negative bacteria, peptidoglycan, lipoteichoic acid from gram 
positive bacteria, lipoarabinomannan from mycobacteria, glycosylphosphatidylinositol 
anchors from Trypanosoma cruzi, a phenol-soluble modulin from Staphylococcus 
epidermis, zymosan from fungi, and glycolipids from Treponema maltophilum (Kumar 
et al., 2009). Studies of TLR2 knockout mice demonstrated the involvement of TLR2 in 
the recognition of peptidoglycan and lipoproteins (Akira et al., 2006). The unique ability 
of TLR2 in being able to recognize such a large variety of microbial components may 
be due to the fact that TLR2 cooperates with other TLRs such as TLR1 and TLR6. Such 
cooperation between TLR2 and other TLRs made it possible for the discrimination of 
the various microbial components (Kumar et al., 2009).  
 
TLR3 
TLR3 is unique in comparison to the other TLRs in that it has a unique signaling 
cascade due to the lack of a conserved proline residue in the cytoplasmic region 
corresponding to proline 712 in the Tlr4 gene. TLR3 plays an important role in 
detecting viral infection as it recognizes double stranded RNA (dsRNA) demonstrated 
by Alexpoulou et al., 2001. TLR3 also promote cross-presentation of virus-infected 
cells through viral dsRNA-mediated activation of DCs (Schulz et al., 2005). Besides, 
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dsRNA, ssRNA from viruses such as West Nile virus, lymphocytic choriomeningitis 
virus (LCMV), vesicular stomatitis virus (VSV), murine cytomegalovirus (MCMV), 
and reovirus can also be recognized by TLR3. However, TLR3 knockout mice do not 
seem to exhibit high susceptibility to infection with these viruses (Edelmann et al., 2004; 
Wang et al., 2004) and there are TLR-independent dsRNA recognition mechanisms.  
 
TLR4  
The discovery of TLR4 started with the observation of mouse C3H/HeJ strain 
displaying hypo-responsiveness towards LPS treatment, leading to the identification of 
the Tlr4 gene (Poltorak et al., 1998). The importance of TLR4 in LPS signaling was 
later confirmed by Hoshino et al., 1999 through knockout mice studies. TLR4 does not 
recognize LPS alone but act in concert with CD14 molecule and MD2 secreted protein 
to bind LPS. LPS binds to LPS-binding protein (LBP) in serum and this complex 
associates with CD14. LPS would also induce CD14 and TLR4 to be in close proximity 
(Jiang et al., 2000; da Silva Correia et al., 2001) while MD2 associates with the 
extracellular portion of TLR4. MD2 is a critical component of the LPS-TLR4 complex 
as MD2 mediates the surface expression of TLR4, affecting the responsiveness of TLR4 
to LPS (Nagai et al., 2002). An additional component, RP105 had been identified to be 
essential for B cells recognition of LPS from knockout mice studies (Nagai et al., 2002). 
However, macrophages from RP105 knockout mice had enhanced response to LPS, 
suggesting RP105 is involved in negative regulation of LPS responses in macrophages 
(Divanovic et al., 2005). TLR4 recognizes other ligands in addition to LPS such as LPS-
mimetic activity of Taxol (Kawasaki et al., 2000; Byrd-Leifer et al., 2001) and together 
with CD14 recognize the fusion protein of respiratory syncytical virus (RSV) (Kurt-
Jones et al., 2000). Heat-shock proteins (HSP) such as HSP60 have been reported to 
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possess immuno-stimulatory activity through TLR4 (Ohashi et al., 2000; Vabulas et al., 
2001; Asea et al., 2002). TLR4 is also involved in the recognition of extracellular matrix 
components produced in response to tissue injury such as extra domain A (EDA) of 
fibronectins and oligosaccharides of hyaluronic acid that are capable in activating 
immune cells (Okamura et al., 2001; Termeer et al., 2002). Hence, TLR4 seem to play 
an important role in the recognition of general endogenous ligands involved in the 
inflammatory response regardless of the source of infection.   
 
TLR5 
TLR5 was first discovered to be involved in recognizing flagellin through a TLR5 over-
expression study in Chinese Hamster Ovary (CHO) cells (Hayashi et al., 2001), 
indicating its importance in the recognition of flagellated bacteria. Subsequently, it was 
discovered that TLR5 recognizes an evolutionary conserved domain of flagellin through 
close contact of the receptor and flagellin (Smith et al., 2003). TLR5 is expressed on the 
basolateral side of intestinal epithelial cells (Gewirtz et al., 2001) and interestingly, 
flagellin is also capable of activating lung epithelial cells to induce inflammatory 
cytokines (Hawn et al., 2003). Besides epithelial cells, TLR5 was found to be expressed 
in CD11c-positive cells residing in the small intestinal lamina propria, suggesting that 
TLR5 is important in the regulation of immune responses against intestinal infections 
(Uematsu et al., 2006).  
 
TLR6 
TLR6 associates with TLR2 as heterodimer to aid in the discrimination of wide variety 
of ligands recognized by TLR2. TNF-α production in response to peptidoglycan but not 
bacterial lipopeptides was inhibited when a dominant negative form of TLR6 was 
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introduced into macrophage cell lines (Ozinsky et al., 2000) though both peptidoglycan 
and bacterial lipopeptides were recognized by TLR2. Macrophages from TLR6 
knockout mice did not respond to mycoplasma-derived diacyl lipopeptides (Takeuchi et 
al., 2001) while the introduction of human TLR2 and TLR6 expression vectors into 
TLR2/TLR6 double knockout embryonic fibroblast cells demonstrated that both TLR2 
and 6 are required for the recognition of mycoplasma-derived diacyl lipopeptides, 
confirming that TLR6 is essential for the recognition of mycoplasma-derived diacyl 
lipopeptides (Kumar et al., 2009).  
 
TLR7 
TLR7 recognizes mainly nucleic acid-like structures. TLR7 was first identified to be 
involved in the recognition of synthetic compounds such as imidazoquinolines used for 
treatment of diseases associated with viral infection (Hemmi et al., 2002). TLR7 was 
later shown to recognize guanosine-, or uridine-rich single stranded RNA (ssRNA) from 
viruses such as human immunodeficiency virus, vesicular stomatitis virus, and influenza 
virus (Diebold et al., 2004; Heil et al., 2004; Lund et al., 2004). Host-derived ssRNAs 
are not recognized by TLR7 as TLR7 is expressed in the endosomal membrane and 
host-derived ssRNA will not be delivered into the endosomal membrane under normal 
circumstances. However, under special circumstances such as autoimmune systemic 
lupus erythematosus (SLE) and Sjörgen syndrome, TLR7 is suspected to be involved in 
the recognition of immune complexes where self-derived ssRNA was conjugated to 
RNA-specific antibody and delivered into the endosome of plasmacytoid DCs, leading 
to the production of IFN-α (Berland et al., 2006; Christensen et al., 2006). There were 
also reports on ssRNA engaging the RNA-specific B cell receptor (BCR) of 
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autoreactive B cells, leading to autoantibody production (Barrat et al., 2005; Lau et al., 
2005; Vollmer et al., 2005).  
 
TLR8 
Human TLR8 is expressed in regulatory T cells (Treg), the activation of TLR8 as found 
to inhibit Treg function (Peng et al., 2005). TLR8 gene is located on the X chromosome 
and is highly homologous to the TLR7 gene. So far, TLR8 has been reported to 
recognize ssRNA and imidazoquinoline, which are also the recognized by TLR7. 
 
TLR9 
TLR9 is essential for the recognition of CpG motif of bacterial and viral DNA (Hemmi 
et al., 2000), dsDNA of virus and hemozoin from plasmodium (Kumar et al., 2009). 
TLR9 has been suspected to be involved in pathogenesis of autoimmune disorders 
(Marshak-Rothstein, 2006), as it is able to facilitate the engagement of IgG2a-chromatin 
complex by the B cell receptor, leading to production of rheumatoid factors (Leadbetter 
et al., 2002).  
 
TLR10 
Human TLR10 has been identified as a member that is closely related to TLR1 and 
TLR6. The ligand of TLR10 has not been identified so far but TLR10 is suspected to be 
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Table modified from (Kumar et al., 2009) 
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1.2.3.2.2 TLR signaling 
Ligand recognition by TLRs leads to the dimerization of TLRs and the recruitment of 
various TIR domain-containing adaptors. The recruitment of adaptors triggers the 
cascade of signaling pathway and ultimately leads to the activation of transcription 
factors such as NFκB and interferon regulatory factors (IRFs); or the activation of MAP 
kinases such as p38, JNKs and ERK1/2, which activates the AP-1 transcription factor. 
The TLR signaling pathway is categorized into MyD88-dependent and MyD88-
independent pathway /TRIF pathway (Akira and Takeda, 2004; Akira et al., 2006; 
Kumar et al., 2009). The pathways engaged by TLRs are shown in Figure 1.8 
 
(i) MyD88-dependent pathway 
The MyD88-dependent pathway is utilized by all TLRs except TLR3. MyD88 possesses 
a C-terminal TIR domain and an N-terminal death domain. MyD88 associated with the 
TIR domain of TLRs upon stimulation and recruits IRAK-4 which would then facilitate 
the phosphorylation of IRAK-1. Activated IRAK-1 associates with TRAF6, leading to 
the activation of two distinct signaling pathways. One pathway leads to the activation of 
the AP-1 transcription factors via the MAP kinases while the other pathway leads to the 
activation of NFκB via the IκB kinase (IKK) complex (Akira and Takeda, 2004). In 
addition, the TIR domain-containing adaptor protein (TIRAP)/MyD88-adaptor like (Mal) 
has been reported to be essential for the MyD88-dependent signaling pathway via TLR2 
and TLR4 (Horng et al., 2002; Yamamoto et al., 2002). 
 
(ii) MyD88-independent pathway / TRIF-dependent pathway 
The MyD88-independent pathway was discovered when TLR4 ligand-stimulated 
MyD88-deficient macrophages showed delayed activation of NFκB (Kawai et al., 1999). 
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This pathway was originally found in TLR3 and TLR4 and activates IRF3, leading to 
the induction of type I interferons.  Recent reports showed the TIR domain-containing 
adaptor inducing IFN-β (TRIF) is essential for TLR3- and TLR4-mediated IRF3 
activation, while TRIF-related adaptor molecule (TRAM) is involved in IRF3 activation 









(iii) TLR-independent recognition of microorganisms 
Several of the pathogens that invade the cytoplasm are capable of evading recognition 
by the TLRs. The mammalian immune system has developed TLR-independent 
cytoplasmic pathogen recognition systems such as nucleotide-binding oligomerization 
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domain (NOD)-leucine rich repeats (LRR) proteins (Inohara et al., 2005) which 
mediates recognition of  peptidoglycan core structures; and RNA helicases (Yoneyama 
et al., 2004) which recognizes viral RNA in the cytoplasm.  
 
1.3 Adaptive Immunity 
1.3.1 Overview of the adaptive immunity 
The innate immunity may be efficient at preventing an infection by significantly 
reducing the pathogen load, but sterile cure or control of an infection requires the 
successful activation of the adaptive immunity (Trinchieri, 2003). The adaptive 
immunity is also referred to as acquired immunity and is composed of randomly 
generated, clonally expressed, highly specialized receptors of seemingly limitless 
specificity (Cooper and Alder, 2006). The adaptive immune system is mainly composed 
of systemic cells and processes that eliminate or prevent pathogenic challenges. The 
innate immune system is limited by the level of immunopathology that can be tolerated 
and hence the adaptive immune system plays a role of increasing the potential efficacy 
of the immune system. This is done by minimizing collateral damage as it focuses on 
immune defense in an antigen-specific manner through the usage of highly specific 
antigen receptors (Palm and Medzhitov, 2009). The adaptive immunity enables host to 
recognize and remember the pathogen encountered (immunological memory), so that a 
stronger immune response can be mounted against the same pathogen upon repeated 
encounters.  
 
The adaptive immune system depends on a process known as somatic hypermutation 
and V(D)J recombination to generate a large repertoire of antigenic receptors that are 
uniquely expressed on the lymphocytes. Randomly generated antigen receptors have the 
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potential to mount an immune response against self antigens. The adaptive immunity 
overcomes this problem through the process of negative selection of autoreactive 
lymphocytes in the thymus. The adaptive immunity will recognize non-self antigens 
during antigen presentation; mount a specific immune response against the invading 
pathogen and at the same time, generate immunological memory of the antigen so that a 
faster and stronger immune response can be mounted against the very same pathogen on 
the next encounter. However, this also means that a delay in response is needed when 
the pathogen is encountered for the first time as the adaptive immunity needs time to 
activate the specific effectors for a response. Antigen receptors of the adaptive immune 
system are uniquely advantageous because it enables the adaptive immunity to 
recognize nearly any antigen and their clonal expansion. The adaptive immune response 
possesses exquisite specificity, maximizing the efficacy of the immune response while 
minimizing unnecessary collateral damage. Clonal expansion and selection of the 
effector cells in adaptive immunity endows the immune system with a mechanism by 
which to remember previous infections and provide future protection (Palm and 
Medzhitov, 2009).  
 
 The cells responsible for adaptive immunity are named lymphocytes with T cells and B 
cells playing a major role. Both T and B cells originate from the same progenitor but 
they play rather different roles in the maintenance of the adaptive immunity. T cells are 
involved in cell-mediated immunity while B cells are involved in humoral immunity 
where antibodies play a large role in the elimination and control of infection (Janeway 
et al., 2005). The T lymphocytes are divided into three populations: (i) CD8+ cytotoxic 




(i) CD8+ cytotoxic T cells 
CD8+ cytotoxic T cells are also known as killer cells because the main responsible of 
these cells is to identify and induce the death of cells infected with pathogen (mainly 
viruses) and cells that are damaged or dysfunctional. Naïve cytotoxic T cells are 
activated when the T cell receptor (TCR) encountered a specific peptide-loaded MHC I. 
The interaction of TCR and MHC I activates the naïve cells to go into clonal expansion, 
proliferate and generate copies of the same effector cell bearing the unique TCR 
recognizing the specific peptide-loaded MHC I on antigen presenting cells. When the 
effector cytotoxic T cells encounter infected cells or damaged cells, these cytotoxic T 
cells would release perforin and granulysin, two enzymes that will cause the infected or 
damaged cells to lyse. Cytotoxic T cells can also induce apoptosis in the infected or 
damaged cells by releasing granzyme. The cytotoxic T cells will be cleared away by the 
phagocytes upon resolution of the infection but some of these cells will remain in the 
circulation as memory cells. The memory cells can differentiate into effector cells 
quickly upon the next encounter of the same pathogen, significantly shortening the 
duration needed to activate a cytotoxic immune response. However, uncontrolled 
activation of the cytotoxic T cell response can cause major damage to the host. Hence, 
the activation of CD8+ T cells would usually require a strong interaction of the TCR-
MHC I or an additional signal provided by the helper T cells. 
 
(ii) CD4+ helper T cells 
Currently there are two sub-populations of the CD4+ helper T cells, each of them 
responsible for the elimination of different type of pathogens, the T helper 1 (Th1) and 
T helper 2 (Th2) cells. Th1 cells are effective against intracellular pathogens such as 
viruses and bacteria. The induction of Th1 response leads to the production of IFN-γ, 
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IL-2, TNF-α and TNF-β, activating bactericidal activities of the macrophages and 
inducing B-cells to produce opsonizing antibodies, activating cell-mediated immunity 
(Szabo et al., 2003). On the other hand, Th2 immune response is effective is dealing 
with extracellular pathogens such as parasite, toxins, helminthes, nematodes and 
extracellular bacteria. Th2 immune response is characterized by the production of IL-4, 
IL-5, IL-6 and IL-13, activating B-cells to produce killing antibodies, leading to the 
activation of humoral immunity. The CD4+ T cells will die and be cleared by 
phagocytes upon the resolution of infection while some of the cells will remain as CD4+ 
memory cells for a faster activation of the T helper immune response. 
 
(iii) gamma-delta-T cells (γδ-T cells) 
γδ-T cells are a unique population of the T lymphocytes as it carries an alternative T cell 
receptor as opposed to the αβ-CD4/CD8 T cells and possesses the characteristics of 
helper T cells, cytotoxic T cells and natural killer cells. The γδ-T cells are able to 
respond to common microbial molecules through the usage of the TCR as pattern 
recognition receptor. 
 
Another important lymphocyte in the adaptive immunity is the B-cells. B-cells produce 
antibodies called immunoglobulins that circulate in the blood or lymph, mediating 
humoral immunity. B-cells produce five different classes of immunolgobulins (Ig); 
immunoglobulin-A (IgA), immunoglobulin-G (IgG), immunoglobulin-M (IgM), 
immunoglobulin-D (IgD) and immunoglobulin-E (IgE). Each immunoglobulin has their 
unique function and are specific for different antigen. B-cells recognizes antigen in their 
‘native’ from as opposed to T cells that recognizes ‘processed’ antigen peptides. B-cells 
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differentiate into antibodies producing-plasma cells upon encountering antigen and 
receiving an additional signal from helper T cells.  
Adaptive immunity is tightly controlled due to the undesirable effects if not properly 
regulated. The innate immune recognition serves as a method of control for the 
regulation of adaptive immunity (Medzhitov and Janeway, 1998; Barton and Medzhitov, 
2002). The adaptive immune responses can be classified into mainly (i) Type I / Th1 
immunity, (ii) Type II / Th2 immunity and (iii) Th17 immunity. There are evidences 
showing that Th1, and Th2 do not derive from distinct lineages but rather they develop 
from the same Th-cell precursor under the influence of environmental and genetic 
factors acting at the level of antigen presentation (Romagnani, 1997). Environmental 
factors such as antigen entry, the physical form of antigen, the type of adjuvant and the 
dose of antigen play a role in the development of Th1 or Th2 immunity while the 
genetic factors remain rather elusive (Constant and Bottomly, 1997). Figure 1.10 shows 
the different cytokines that influence the development of a naïve CD4 T cell into Th1, 
Th2 or Th17 immunity. Naïve CD4 T cells develop into Th1 cells in a cytokine 
environment of IFN-γ and IL-12. These two cytokines are mainly produced by 
macrophages and DCs. IL-4 and IL-2 would favour the development of CD4 T cells into 
Th2 cells while development of Th17 cells requires the cytokines TGF-β, IL-6 and IL-
21. The role of cytokines and the development of Th1, Th2 and Th17 immunity will be 
further explored in the next few sections. 
 
1.3.2 Th1 immunity 
The type I or Th1 immunity is also known as cell-mediated immunity. While CD8 T 
cells are already predestined to become cytotoxic cells as they leave the thymus, the 
naïve CD4 T cells can differentiate into either Th1 or Th2 cells. This is crucial in 
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determining whether a cell mediated immunity or humoral immunity will predominate 
as the appropriate immune response. The Th differentiation pathway is influenced by 
various factors upon TCR engagement. The type of APC encountered, the concentration 
of antigen (duration, strength and signal), the ligation of specific co-stimulatory 
molecule, and the local cytokine environment are all able to affect the Th cell 
differentiation process (Szabo et al., 2003). Th1 cells produce IFN-γ and are mainly 
involved in the protection against intracellular microbes (Abbas et. al., 1996). 
 
1.3.2.1 Effectors of Th1 Immunity 
DCs are the key regulator of Th1 immunity. Cells of Th1 immunity secrete cytokines 
such as IFN-γ, IL-2, TNF-α and TNF-β, which are critical in the eradication of 
intracellular pathogens and viral infection. Excessive Th1 response has been associated 
with tissue destruction in autoimmune disease due to over-production of cytokines. IL-2 
promotes T cell growth. IFN-γ activates macrophages and MHC expression while 
increasing IgG production. TNF-α and TNF-β activates macrophages and nitric oxide 
production. All these work together to defend against the invading intracellular 
pathogens (Janeway, 2002).  
 
An important determining factor of Th1 development in CD4+ T cells is STAT4 
activation by IL-12. Two physiological pathways have been described for inducing IFN-
γ production by T cells. The first pathway is the TCR pathways and the second pathway 
is the engagement of IL-12-IL-18 signaling. CD8+ T cells produce IFN-γ independently 
of STAT4 activation and of IL-12 when activated through the TLR pathway whereas 
CD4+ T cells require STAT4 for activation. However, both CD4+ and CD8+ T cells 
require STAT4 activation for the induction of IFN-γ through the IL-12-IL-18 signaling 
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pathway (Yang et. al., 1999; Carter et. al., 1999). STAT4 can be activated by either IL-
12 or type I interferons such as IFN-α in humans (Cho et. al., 1996).  
 
1.3.3 Th2 Immunity 
The Th2 immunity is critical in protection of the host against gastrointestinal nematodes, 
extracellular parasites and also responsible for allergic disorders (Romagnani et. al., 
1997). Th2 immunity produces mainly IL-4, IL-5, IL-9 and IL-13 which are important 
for a strong antibody response. Th2 immune response inhibits the activation of Th1 and 
macrophage activity as attempts to destroy large parasites through Th1 responses and 
excessive macrophage activity would be harmful to the host. (Gordon and Taylor, 2005). 
IL-4 induces the differentiation of Th-cells into Th2 cells when the concentration of IL-
4 reaches a necessary threshold because the inducing effect of IL-4 dominates over 
other cytokines (Romagnani, 1997). Th2 development requires the signaling pathway of 
IL-4 and STAT6 with GATA-3 as the transcription factor. IL-4-independent and 
STAT6-independent development of Th2 has also been observed in various studies both 
in vivo and in vitro (Finkelman, et. al., 2000; Ouyang et al., 2000). GATA-3 is able to 
maintain its own expression through an autoactivation loop while STAT6 acts as a 
repressor for GATA-3 (Rodriguez-Palmero et. al., 1999; Ouyang, et. al., 1998). Hence, 
Th2 has been assumed to be the default pathway when IL-12 signaling is absent.  
 
1.3.3.1 Effectors of Th2 Immunity 
The effectors of Th2 immunity include IL-4 which stimulates the growth of B cells, T 
cells, and mast cells. IL-4 also inhibits macropinocytosis while activating the production 
of IgG1 and IgE. Figure 1.9 shows the engagement of TCR and its downstream 
signaling upon activation of the IL-4 receptor (IL-4R). The IL-4R signals through Stat6 
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while the TCR/CD3/CD28 complex activates the NF-κB pathway, activating the 
GATA3 promoter which will then favour a Th2 environment, producing Th2 cytokines. 
IL-5 is another effector of Th2 immunity and is actively involved in the stimulation 
growth and differentiation of eosinophils, increasing the production of IgA. IL-10 
promotes the activation of Th2 immunity while inhibiting Th1 activation and inhibits 
cytokine release (Kapsenberg et. al., 2003).  IL-6 and TGF-β are also important 
effectors of the Th2 immunity. TGF-β inhibits B cell growth, promotes IgA production, 
inhibits T cell growth, promotes T cell survival, inhibits macrophage activation, 
activates neutrophils, inhibits or activates other somatic cells (Janeway, 2002). 
 
1.3.4 Th17 Immunity 
Th17 cells have been named so because of their ability to produce IL-17 though the 
signature cytokines for Th17 cells are IL-17 and IL-22 (Zhu et. al., 2010). Th17 has 
been shown to be critical in their involvement in the pathogenesis of autoimmune 
diseases such as rheumatoid arthritis (Cua et. al., 2003). IL-17 promotes granulopoiesis 
and neutrophil accumulation. IL-17 also plays an important role in inflammatory 
disorders while offering protection to the mucosal barrier due to the ability in 
stimulating the formation of tight junction and secretion of mucin (Chen et al., 2003). 
Th17 cells represent a distinct lineage that originates mainly in the presence of TGF-β 
and IL-6. IL-23 is crucial for the expansion and maintenance of the Th17 cells but not 
the initial differentiation of Th17 cells. The IL-23 receptor has found to be only 
expressed after the naïve T cells have partially completed the Th17 differentiation (Zhu 
et. al., 2010). Th17 cells are controlled by the transcription factor Foxp3 (Zheng and 
Flavell, 1997). Th17 cells have been shown to be involved in the defense mechanism of 
certain pathogen, especially pathogens endangering the epithelial surface (Happel et. al., 
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2005; Huang et. al., 2004). Th17 immunity has also been suggested to play a critical 
role in the development of autoimmune diseases (Langrish et. al., 2005). Th17 cells 
originate from the same Th-cells precursor but under different polarizing conditions 
which is determined at the early presence at the time of antigen presentation (Seder and 
Paul, 1994). Subsets of cells sharing features of both Th1 and Th17 have been identified 
with IL-12 suggested as the key modulator of the development of these cells 
(Annunziato et. al., 2007).  
 
1.3.4.1 Effectors of Th17 Immunity 
IL-23 is produced primarily by the APCs (macrophages and DCs) in response to TLR 
molecules. IL-23 is a member of the IL-12 cytokine family and it shares the p40 subunit 
with IL-12 as a heterodimer with p19 instead of p35. The IL-23 receptor is expressed 
mainly on memory T cells. IL-23 directs the development of Th17 T cells together with 
TGF-β and IL-6 (Garrett et. al., 2008). Although IL-23 appeared to be required for Th-
17-mediated immunopathology, recent reports have indicated that IL-23 is not required 
for Th17 commitment, but rather appears to be important for the amplification and 
stabilization of the Th17 phenotype (Aggarwal et. al., 2003; Weaver et. al., 2006). The 
cytokines crucial for driving the differentiation of Th17 cells are TGF-β and IL-6.  
 
1.4 Dendritic cells in Th1, Th2, and Th17 Induction  
Dentritic cells as professional APCs play a major role in determining the immune 
response. DCs are the only APCs that are capable of migrating to the lymph nodes for 
antigen presentation. DCs are crucial for presenting antigens encountered by the host to 
naïve T cells and hence determining the expansion of Th1, Th2 or Th17 cells. DCs are 
also important for the induction of immunological tolerance through the involvement in 
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the mechanisms of clonal deletion of self-reactive T cells in thymus; and clonal deletion 
and anergy through the production of regulatory T cells (Weaver et. al., 2006; Steinman 
and Nussenzweig, 2002; Roncarolo et. al., 2001). The diverse functions of DCs in 
immune regulation reflect the heterogenous subsets with different lineages and maturity, 
and functional plasticity (Sato and Fujita, 2007). There had been two opposing views on 
the activation of T cells by DCs. The first view holds that distinct subsets of DCs were 
predetermined to differentially bias the T helper response while the second view 
suggests that microbes and the local microenvironment are potent modulators of DCs 
function and hence affect T cell activation (Moser and Murphy, 2000).  
 
Human DCs differentiate from two distinct types of precursor in culture: monocytes 






 plasmacytoid cells (lymphoid lineage). Both 
DC types are able to induce strong proliferation of naïve CD4+ T cells (Grouard et. al., 
1997). The subclass of DCS used to stimulate T cells in vitro determines the nature of 





 T cells cultured with monocyte-derived DCs are potent in IFN-γ 
production while T cells cultured with plasmacytoid-derived DCs produced large 
amounts of IL-4, IL-5 and IL-10 (Moser and Murphy, 2000).  
 
Among the factors shown to influence the balance between Th1 and Th2, IL-12 is the 
dominant cytokine in directing the development of Th1 cells which produce large 
amounts of IFN-γ. DCs function simultaneously as APCs and IL-12-producing cells 
which will then induce the development of Th1 cells, promoting a Th1 immune 
response (Moser and Murphy, 2000). T cell priming by DCs require engagement of 
CD28 by CD80 or CD86 and the IL-12 produced by DCs is a potent and obligatory 
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inducer of the differentiation of IFN-γ-producing cells in vivo (De Becker et. al., 1998). 
DCs undergo a refractory state after systemic triggering of the Th1 cells in which DCs 
are no longer capable of producing IL-12. The paralysis of IL-12 production may 
constitute a feedback mechanism to limit the immunopathology associated with 
prolonged exposure of IL-12 which would be detrimental to the host (Kalinski et. al., 
1999).  
 
The role of DCs in Th2 development has been rather controversial. Earlier studies had 
shown that splenic DCs and macrophages are capable of producing IL-6, which would 
drive the differentiation of Th2 cells (De Becker et. al., 1998; Rincón et. al., 1997). 
However, blocking IL-6 does not prevent IL-4 induction by DCs, but abrogates the 
activation of Th2-type cells by macrophages. Th2 development does not seem to require 
APC-derived IL-4 and activated plasmacytoid-derived DCs do not seem to produce 
detectable amount of IL-4 (Schmitz et. al., 1994; Rissoan, et. al., 1999).  Hence, there 
are hypothesis that Th2 is the default pathway and that Th2 cells would develop 
spontaneously in the absence of IL-12. Human DC2 subset appears to drive Th2 
development even in the absence of IL-4 (Rissoan et. al., 1999). Th2 development 
requires the signaling pathway of IL-4 and STAT6 with GATA-3 as the transcription 
factor. IL-4-independent and STAT6-independent development of Th2 has also been 
observed in various studies both in vivo and in vitro (Finkelman, et. al., 2000; Ouyang et 
al., 2000). GATA-3 appears to have an autoactivation loop that is able to maintain its 
own expression while STAT6 appears to be able to repress GATA-3 (Rodriguez-
Palmero et. al., 1999; Ouyang, et. al., 1998). Hence, Th2 has been assumed to be the 




The role of DCs in Th17 development has been studied extensively in recent years after 
the characterization of IL-17 producing Th17 cells. Th17 has been shown to be critical 
in their involvement in the pathogenesis of autoimmune diseases such as rheumatoid 
arthritis, inflammatory disorder and mucosal immunity. DCs derived IL-23 had been 
thought to be the critical factor for the induction of Th17 immune response as IL-23 
increases the production of IL-17 from activated CD4
+
 T cells (Aggarwal et. al., 2003; 
Langrish et. al., 2005). Recent studies had shown however, that IL-23 does not induce 
the differentiation of Th17 cells but rather TGF-β and IL-6 are the important factors in 
Th17 differentiation (Veldhoen et. al., 2006). DCs have been thought to be important for 
the development of Th17 cells because of the generation of IL-17 producing CD4 T 
cells in the presence of LPS, a TLR ligand. Besides, ligands for TLR3 and TLR9 have 
also been shown to be capable in inducing the differentiation of IL-17 producing cells 
(Veldhoen et. al., 2006). This study suggests that DCs stimulated by TLR ligands 









Figure 1.9 Major pathways in the regulation of T cells development with the Th2 
phenotype. Transcription factor GATA-3 appears to be central to the Th2 response with 
an autoactivation mechanism, stabilizing the Th2 phenotype through an intracellular 
positive feedback loop (Farrar et. al., 2002). 
Figure 1.10 The role of cytokines in differentiation and effector functions of Th1, Th2 
and Th17 cells. CD4+ T cells differentiate into distinct Th lineages in the context of 
combinations of cytokines upon TCR activation. The differentiation processes involve 




1.5 Dimethyl Sulfoxide (DMSO) 
 
Dimethyl sulfoxide (DMSO, [(CH3)2SO]) is an amphipathic molecule with a highly 
polar domain and two apolar methyl groups. Hence, DMSO is soluble in both aqueous 
and organic media. This unique property had made DMSO a widely used solvent for the 
administration of water-insoluble-subtances in vivo. The other important characteristic 
of DMSO is that it is a hydrogen–bound disrupter (Santos et al., 1997) and an 
antioxidant, making it an important chemical in both the laboratory and clinical settings 
such as its applications as cyroprotectant, cell differentiating agent, hydroxyl radical 
scavenger, intercellular electrical uncoupler, intracellular low-density lipoprotein-
derived cholesterol mobilizing agent, solubilizing agent used in sample preparation for 
electron microscopy, antidote to the extravasation of vesicant anticancer agents, and 
topical analgesic (Santos et al., 2003).  
 
(i) DMSO applications in industry 
DMSO is a by-product of paper and pulp production. DMSO is currently the most 
commonly used solvent in industry for paint stripping. There has been an increase in the 
applications of DMSO in the electronic and microelectronics industry such as flat panel 
displays (Kvakovszky et. al., 2007). 
 
(ii) DMSO medical applications  
DMSO has been extensively debated over its potential as a medicine. Over the years, 
DMSO has been used in various medical conditions since DMSO was first discovered to 
be able to penetrate the skin easily without causing much damage to the skin (Kolb et. 
al., 1967). Nevertheless, there had been many critics and controversies over its efficacy 
and potential side effects as a medicinal drug (Herschler et. al., 1980). DMSO had been 
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used as a veterinary medicine for horses in treatment of pain and intracranial pressure. 
In humans, DMSO had been on clinical trials for its application as a topical analgesic 
(Lockie et. al., 1967), as an anti-inflammatory drug (Salim et. al., 1992), in the 
treatment for scleroderma (Scherbel et. al., 1967). DMSO had also been studied for its 
potential in the pain relief of arthritis patients (Matsumoto et. al., 1967) and treatment of 
trauma to the central nervous system (de la Torre, et. al., 1975). DMSO has also been 
proposed to play a role in cancer treatment due to its antioxidant properties (Salim et. al., 
1992). DMSO has been found to be able to decrease metastasis of line 1 lung carcinoma 
murine tumour cells (Cerosaletti et. al., 1990). DMSO also increased the immune 
recognition of H-2 antigen-deficient murine lung carcinoma cells (Bahler and Lord, 
1985). However, clinical trials with DMSO have not been supported due to its possible 
toxicity and side effects, resulting in the limitation of developing DMSO as a medicinal 
drug. Thus far, DMSO has only been approved for its use in the symptomatic pain relief 
of interstitial cystitis. The ability of DMSO to penetrate membranes has led to the 
investigation of DMSO as a potential drug delivery system. DMSO had also been 
proposed as a potential novel strategy for coating drug-eluting stents in the treatment of 
acute coronary symptoms as it was shown to inhibit tissue factor expression, thrombus 
formation and vascular smooth muscle cell activation (Camici et. al., 2006). Neverthelss, 
the potential of DMSO emerging as a drug is still faced with many skepticism. 
 
(iii) Biomedical applications of DMSO 
DMSO is currently widely used in the storage of cell lines as it is an effective 
cryoprotectant. DMSO is able to protect the cells from freeze-induced damage and death 
due to its ability to penetrate the cell membrane. DMSO penetrates the cell membrane 
and partially solubilize the cell membrane preventing puncture of the cell and minimize 
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the formation of ice crystals during the freezing process. DMSO on its own appears to 
be non-toxic (Vignes, 2000). Nevertheless, DMSO has been reported to be toxic to cells 
at high concentrations causing certain side effects (Zhang and Eyzaguirre, 1999). 
Despite of its side effects, it offers protection to the cryopreserved cells. The 
cryopreservation of live cells is a delicate and important technique. High quality 
cryopreserved cells are not just important for cellular research purposes but is extremely 
crucial with the advancement of cellular therapies using live cells such as 
immunotherapy. Very often the success of these medical procedures depends on the 
ability to freeze and store live cells for future use. In addition, DMSO is used in 
polymerase chain reactions (PCR) to inhibit formation of secondary structures in the 
DNA (Chakrabarti et. al., 2001).  (Heckert et. al., 2002) reported that DMSO enhanced 
the liposome-meidated transfection of nucleic acid in chicken macrophage cells. 
 
(iv) DMSO effects on the immune system 
DMSO has been used in many medical applications. Hence, it is important to investigate 
the short and long term effects of DMSO on the immune system. DMSO was reported 
to be capable of inhibiting LPS-elicited IL-8 production in human whole blood (Laura et. 
al., 1993) and bone marrow derived-macrophages from mice (Keiran et. al., 2004). The 
ability of DMSO in suppressing LPS-elicited IL-8 production was attributed to its 
antioxidant property. Fresh human whole blood containing DMSO and DMSO cryo-
preserved human whole blood both demonstrated an increase in IL-1β and IL-6 
production (Stefanie et. al., 2004). In contrast, DMSO was also reported to inhibit TNF-
α induced IL-6 production in both airway epithelial cells and lung fibroblast (Yoshida et. 
al., 1999). (Kubin et al., 1994) reported that DMSO could enhance LPS-elicited IL-12 
production by human myeloid leukemia cell lines and primary peripheral blood 
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mononuclear cells. In vivo, dendritic cells (DCs) are major producers of IL-12 which is 
key to the induction of Th1 type of immunity. DMSO was also found in inhibit adhesion 
of larval haemocytes to slides at high concentrations (Dunphy et. al., 2007).  
 
1.6    Aims of Study 
The aim of this thesis is to study: 
(i) DMSO effect on cell survival and profile 
Dimethyl sulfoxide (DMSO, [(CH3)2SO]) is an amphipathic molecule with a highly 
polar domain and two apolar methyl groups. Hence, DMSO is soluble in both aqueous 
and organic media. This unique property had made DMSO a widely used solvent for the 
administration of water insoluble-subtances in vivo. The other important characteristic 
of DMSO is that it is a hydrogen–bound disrupter (Santos et al., 1997), making it an 
important chemical in both the laboratory and clinical settings. Other common uses of 
DMSO are such as cyroprotectant, cell differentiating agent, hydroxyl radical 
scavenger, intercellular electrical uncoupler, intracellular low-density lipoprotein-
derived cholesterol mobilizing agent, solubilizing agent used in sample preparation 
for electron microscopy, antidote to the extravasation of vesicant anticancer 
agents, and topical analgesic (Santos et al., 2003). DMSO has been known to possess 
various toxic effects on human kind. It has been reported that DMSO differentiated HL-
60 cells displayed changes in their antigen expression (Ian et al., 1998). This study aims 







(ii) The role of DMSO in DC and Macrophage activation 
DMSO has been shown to stimulate cytokine production when employed as a 
differentiating agent. DMSO differentiated HL-60 cells were responsive to 
Saccharomyces cerevisiae and Candida albicans stimulation and secreted pro-
inflammatory cytokines such as IL-1β, IL-12, IL-18 and TNF-α (Saegusa et al., 2009). 
In addition, it has also been reported that pre-treatment of human myeloid leukemia cell 
lines and peripheral blood mononuclear cells with DMSO enhanced the production of 
IL-12 (Kubin et al., 1994). Both DCs and macrophages are involved in antigen 
presentation, while DCs are potent IL-12 producers upon activation. This study hence 
aims to investigate the effect of DMSO pre-treatment on the activation of antigen 
presenting cells in inducing an immune response. 
 
(iii) DMSO effect on DC histone protein 
Mammalian development and cellular differentiation are controlled epigenetically by 
DNA methylation and histone modifications. Since DMSO has been reported to affect 
cellular functions and cell differentiation, it is highly possible that DMSO affects the 
epigenetic profile. Studies carried out on mouse embryoid body suggest that DMSO is 
capable of altering DNA methylation profiles with upregulation of Dnmt3a expression 
while accompanied by phenotypic changes (Iwatani et al., 2006). This study proceeds to 
study if DMSO is able to induce any histone modifications on immune cells, especially 










CHAPTER 2 MATERIAL AND METHODS 
 
2.1 Materials 
LPS was obtained from Sigma-Aldrich (St Louis, IL). Recombinant human Interleukin-
four (rhIL-4), interferon-gamma (IFN-γ), macrophage colony-stimulating factor (M-
CSF) and granulocyte/macrophage colony-stimulating factor (GM-CSF) were obtained 
from R&D Systems Inc. (McKinley Place N.E., MN). The following mouse monoclonal 
antibodies were obtained from Ancell Co. (Bayport, MN): CD1a (FITC), CD14 (FITC), 
CD40 (FITC), CD86 (FITC), MHCII (FITC), CD54 (FITC), and CD83 (PE). CD80 
(PE) and CD83 (PE) mouse monoclonal antibodies were purchased from BD 
Pharmingen. Anti-histone antibodies (anti-H3, anti-H2A, anti-H2B, anti-H4), di-
methylated-histone antibodies kit, acetylated-histone antibodies kit and mitotic marker 
(phosphorylation) histone antibodies kit were purchased from Cell Signaling 
Technology Inc. (Beverly, MA). Purified-pan-H3 was obtained from Upstate Millipore 
(Billerica, MA). DMSO was obtained from Applichem GmbH (Darmstadt, Germany). 
 
2.1.1 Bacteria culture and preparation 
E.coli DH5α was obtained from Invitrogen and cultured in Luria-Bertani (LB) broth at 
37°C overnight with shaking. The bacteria were harvested by centrifugation for 10 min 
at 2000 g, washed and re-suspended in PBS at 1.75 x 10
8
/ml. Bacteria density was 
determined by measurement at 600 nm. 
 
2.2 Buffers and Media 




HI-media – RPMI-1640 or DMEM with 10% heat-inactivated BCS and 1% penicillin-                   
streptomycin 
Serum free media – RPMI-1640 or DMEM with 1% penicillin-streptomycin 
MACS running buffer – Phosphate buffered saline (PBS) pH 7.2 with 0.5% BSA and 
2mM EDTA  
Freezing Media – Complete RPMI or DMEM with 10% DMSO 
Western Blotting Buffer – 25 mM Tris-HCl with 150 mM glycine and 20 % (v/v) 
methanol 
Western Blot Washing Buffer (TBST) – 10 mM Tris-HCl, 100 mM NaCl, pH 7.4 with 
0.05% Tween-20 
Western Incubation and Blocking Buffer – 5% (w/v) non-fat milk in TBST 
Hypotonic Lysis Buffer – 10 mM Tris-HCl pH 8.0, 1 mM KCl, 1.5 mM MgCl2 and 1 
mM Dithiothreitol (DTT) 
Western Blot Striping Buffer – 62.5 mM Tris-HCl pH 6.8, 2% SDS, 0.1 M β-
mercaptoethanol 
 
2.3 Cell Culture Techniques 
2.3.1 Isolation of Human Peripheral Blood Monocytes 
Peripheral blood leukocytes were obtained in the form of buffy coat preparations 
derived from healthy donors from the NUH Blood Donation Centre. Monocytes were 
isolated from the buffy coats as previously described (Cao et al., 2005). Briefly, buffy 
coats were diluted two-fold in PBS and subjected to centrifugation through a Ficoll-
Paque gradient (Amersham Biosciences Corp, Piscataway, NJ). Peripheral blood 
mononuclear cells (PBMCs) at the gradient interface were collected and washed four 
times with PBS to remove platelets. Washed cells were then re-suspended at a volume 
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of 2-3 x 10
6
/ml in RPMI containing 5% (v/v) iron-supplemented bovine calf serum 
(BCS) (Hyclone) and incubated for two hours in T75 tissue culture flasks at 37°C, five 
percent (5%) CO2. Non-adherent cells which are mainly lymphocytes are removed by 
washing with warm 5% media. The adherent fraction of monocytes is then harvested 
while the non-adherent fraction of peripheral blood mononuclear cells are collected and 
used for further experiments such as T cells isolation and histone protein isolation. 
 
2.3.2 Isolation of CD4
+
 T Cells 
Non-adherent fraction of peripheral blood mononuclear cells was collected and CD4
+
 T 
cells were isolated according to manufacturer’s (Miltenyi Biotech, Bergisch Gladbach, 
Germany) protocol. Briefly, cells were washed and counted before re-suspending cells 
at a density of 1 x 10
7
/ml in 40 µl of running buffer (phosphate buffered saline (PBS), 
pH 7.2 supplemented with 0.5% BSA and 2 mM EDTA). 10 µl of Biotin-antibody 
cocktail was added and incubated on ice for 10 minutes. Another 30 µl of running buffer 
was added and 20 µl of anti-biotin microbeads were added followed by 15 minutes of 
incubation on ice. Cells were washed with 20x labeling volume and centrifuge at 300 g 
for 10 minutes. Supernatnant was discarded and cells re-suspended at a density of 
maximum 1 x 10
8 
cells per 500 µl buffer. Cell separation was carried out with the 
autoMACS
TM
 Separator (Miltenyi Biotech) using the “depletes” programme. Negatively 
labeled CD4
+
 T cells were collected at the negative port and this constitutes the fraction 
of isolated CD4
+
 T cells. 
 
2.3.3 Monocyte Differentiation - Macrophages and DCs Culture 
Isolated monocytes were re-suspended at a density of 1 x 10
6
/ml in RPMI containing 
10% (v/v) BCS, 100 units/ml penicillin, 100µg/ml streptomycin, two (2) mM L-
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glutamine, one (1) mM sodium pyruvate, and 0.0012% (v/v) 2-mercaptoethanol 
(complete cocktail RPMI). Macrophages were cultured from isolated monocytes in the 
presence of M-CSF (20 ng/ml) (R&D) for a period of six days. These are known as M-
CSF macrophages.  Macrophages were also cultured for six days in the presence of GM-
CSF (40 ng/ml) (R&D) (GM-CSF macrophages). The MGM-macrophages were 
cultured in complete cocktail RPMI with 20 ng/ml of both M-CSF and GM-CSF. DCs 
were cultured in the presence of GM-CSF (20 ng/ml) and rhIL-4 (40 ng/ml) (R&D) for 
six days, known as GM-DC. M-DC refer to DCs cultured in the presence of M-CSF (20 
ng/ml) and rhIL-4 (40 ng/ml). Monocytes were cultured in M-CSF (20 ng/ml), GM-CSF 
(20 ng/ml) and rhIL-4 (40 ng/ml) to generate MGM-DC. Half of the culture media 
volume was replaced with fresh media every other day.  
 
2.3.4 Cell Lines Culture 
2.3.4.1 Human Monocytic Cell Line (THP-1)  
Human monocytic cell line, THP-1 was cultured in RPMI-1640 supplemented with 
10 % (v/v) BCS, 100 units/ml penicillin, 100µg/ml streptomycin, and two (2) mM L-
glutamine.  
 
2.3.4.2 Human Embryotic Kidney 293 T Cell Line (HEK 293T) 
Human embryonic kidney 293T cell line (HEK 293T) was cultured in DMEM 
supplemented with 10% (v/v) BCS, 100 units/ml penicillin, 100 µg/ml streptomycin, 






2.3.4.3 Cryopreservation of Cell Lines 
(A) Suspension Cells 
Cells in log phase were adjusted to a density of 5 x 10
6 
cells / ml of freezing medium 
(complete media with 10% DMSO). The cell suspension was aliquot into cryogenic 
storage vials and transferred to -80°C for short-term storage. Cells for long term storage 
were first stored at -80°C overnight before transfer to a liquid nitrogen tank. 
(B) Adherent Cells 
Cells were detached from flask with trypsin or through mechanical scraping and re-
suspended in complete medium. Cells were centrifuged at 300 g for 5 minutes. The cells 
were re-suspended in freezing medium at a density of 5 x 10
6 
cells / ml, aliquoted into 
cryogenic storage vials and stored either at -80°C or in a liquid nitrogen tank.  
 
2.3.4.4 Thawing of Cryopreserved Cells 
Cells were removed from storage and thawed quickly in a 37°C water bath. Cells were 
then transferred quickly into 10 ml of complete media and centrifuged at 300 g for 5 
minutes. The supernatant was discarded and the cell pellet re-suspended in fresh 
complete media at a density of 1 x 10
6 
/ ml. Cells were then grown in a 37 °C 
humidified tissue culture incubator in the presence of 5 % CO2. 
 
2.3.5 Priming and Activation of Monocyte, Macrophage and Dendritic Cell 
Cells were harvested and re-suspended at 1 x 10
6 
/ ml in HI-RPMI and cultured in 24-
well plates (0.5 ml/well) or 96-well plates (0.1 ml/well). Activation was assessed by 
increased expression of CD83, CD80 and CD86 for DCs and increased expression of 




(A) Activation with Lipopolysaccharide (LPS) 
Cells were activated with 1 µg/ml of LPS for 24 hours for the study of cytokine 
production or 48 hours for study of surface molecule expression. 
(B) Activation with Interferon-gamma (IFN-γ) and LPS 
Cells were primed with IFN-γ (500 ng/ml) for 10 min before activation with LPS as (A) 
(C) Activation with Escherichia coli DH5α 
Cells were activated with DH5α at a multiplicity of infection of 20 bacteria to 1 cell for 
24 hours and the cytokine production was studied by ELISA.  
(D) Priming of Dendritic Cells with Dimethyl-sulfoxide (DMSO) 
DCs were primed with 1 % DMSO for 2 to 24 hours depending on experiment before 
the addition of IFN-γ and LPS activation. 
 
2.3.6 Generation of anti-CD3/anti-CD28 coated beads 
Polybead® Microspheres 2.00 µm (Polysciences, Inc., PA) latex beads (calculated to 
the amount to be used in a ratio of 2 beads to 1 T cell) was re-suspended in 1 ml serum 
free media and centrifuged at 14000 rpm for 5 minutes for washing. Supernatant was 
removed and beads re-suspended in 1 ml of PBS. 0.1 µg anti-human CD3 and 0.1 µg 




T cells were added to beads and incubated 
at 37°C CO2 incubator for 2 hours for coating. Beads were then re-suspended in 1ml 
culture media and centrifuged at 14000 rpm for 5 minutes. Supernatant was removed 
after washing and beads re-suspended to a volume such that every 200 µl of HI-RPMI 






2.3.7 Mixed-Leukocyte Reaction (MLR) 
Dendritic cells were harvested and re-suspended at 1 x 10
5 
/ ml in HI-RPMI and 
cultured in 96-well round bottom plates (0.1 ml/well). Freshly isolated CD4+ T cells 
were washed and re-suspended at a density of 1 x 10
6
/ml in HI-RPMI and seeded into 
the same 96-well round bottom plate (0.1 ml/well). The ratio of DC to T cells was 1:10. 
Cells were primed with DMSO (1%), IFN-γ (500 ng/ml) before activation with LPS (1 
µg/ml) or directly stimulated with DH5α (20:1 cell). Supernatant was harvested after 
seven days and cytokine production was measured with ELISA. For re-stimulation of 
the cells, the supernatant will be harvested after 7 days and the cells will be washed. 
Fresh HI-RPMI containing anti-CD3/anti-CD28-coated beads (Refer Section 2.3.6) will 
be added to the cells in a ratio of 2 beads to 1 T cell. The reaction will be carried out for 
another 3 days and the supernatant harvest for cytokine assay by ELISA. 
 
2.4 Immuno-detection of Proteins 
2.4.1 Western Blotting 
Proteins were separated on a 12.5% or 15% acrylamide gel by SDS-PAGE before 
transferred into blotting buffer (25 mM Tris-HCl / 150 mM glycine with 20% (v/v) 
methanol). The gel was laid flat onto a methanol-pre-soaked polivinylidene fluoride 
(PVDF) transfer membrane and sandwiched between two wet filter papers in a western 
blot cassette. Electro-transfer was carried out at 100 V for 2 hours in cold blotting buffer. 
Upon completion of transfer, PVDF membrane was rinsed briefly in TBST and 
incubated with blocking buffer (5 % non-fat milk in TBS-T) for 1 hr at RT. Membrane 
was then incubated with primary antibody in incubation buffer (5 % non-fat milk in 
TBS-T or 5 % BSA in TBST-T) on a shaking platform overnight at 4 °C or 2 hour RT. 
Blots were then rinsed with washing buffer for 3 x 10 minutes at RT before proceeding 
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with incubation of secondary antibody diluted in incubation buffer. Secondary antibody 
incubation was carried out for 1 hour at RT and blots were then washed as before. Blots 
were then incubated with alkaline phosphatase substrate for 5 minutes and protein bands 
were exposed onto an x-ray film. Film was then developed in the dark with film 
developer Konica Minolta SRX-101A for visualization of protein bands. 
 
2.4.2 Protein Stripping from Western Blot 
PVDF blots were washed in western washing buffer before incubation in western blot 
protein stripping buffer. Protein stripping was carried out for 15 to 30 min at 50 °C in a 
water bath. Blots were then washed with washing buffer for 3 x 10 min before 
incubation with western blocking buffer and continued with the remaining steps of 
western blotting.  
 
2.4.3 Flow Cytometry Analysis 
2.4.3.1 Detection of Surface Proteins 
Cells such as adherent DCs and macrophages were harvested by scraping and combined 
with cells in suspension. Monocytes were harvested after 2 hour adhesion during the 
monocytes isolation from buffy coats. The cells were washed twice with cold PBS and 
re-suspended in cold HI-RPMI at 5 x 10
6 
/ ml. A fraction of 50 µl of the cells was 
incubated with a specific fluorochrome-conjugated-antibody for 45 minutes on ice. 
Cells to be incubated with purified antibodies were blocked with 20% (v/v) goat serum 
before primary antibody incubation and washed before proceeding with secondary 
antibody incubation. The cells were then wash for another two times with cold PBS and 
resuspended in cold 1% (w/v) paraformaldehyde (PFA) in PBS. Cells were analyzed on 
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FACScalibur using the CellQuest software (BD Bioscience, San Jose, CA) or Dako 
Cyan with Summit version software 4.3 (Dako, Stockport). 
 
2.4.3.2 Detection of Intracellular Proteins 
Detection of intracellular proteins was similar to the procedure of surface proteins 
detection with a few additional steps. Cells were harvested, washed, and fixed with 1 % 
PFA (w/v) for 15 min on ice. Cells were then permeabilized with 0.2% (w/v) saponin 
before blocking or antibody incubation. Cells were then washed with cold PBS where 
washing and fixing steps were performed as mentioned in Section 2.4.3.1  
  
2.4.3.3 Detection of Intracellular Cytokine 
Intracellular cytokine detection was carried out with the according to manufacturer’s 
instruction (BD Pharmingen, NJ, USA). Cells cultured in round bottom 96-well plate 
were washed with HI-RPMI and centrifuged at 2000 g x 3 min. Supernatant was 
removed and 150 µl of HI-RPMI supplemented with  0.1 µg/ml of phorbol 12-myristate 
13-acetate (PMA) and 1 µg/ml of ionomycin was added to each well 6 hours before 
cells will be harvested for staining. Brefeldin A (Sigma, Saint Louis, IL) (10 µg/ml) was 
added to each well 2 hours after stimulation with PMA and ionomycin to prevent the 
secretion of cytokines. Cells were washed 6 hours after PMA and ionomycin stimulation. 
Cells were fixed and permeabilized with 100 µl / well of Fix/Perm buffer (provided in 
kit) for 20 min. Cells were washed 3 times before re-suspended into washing buffer with 
the corresponding fluorochrome-conjugated antibody (e.g., IFN-γ-PE). Staining was 
allowed to proceed for 30 min and cells were washed before re-suspended in staining 
solution and transferred to Dako flow cytometry tubes. Cells were analyzed on Dako 
Cyan with Summit software version 4.3 (Dako, Stockport). 
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2.4.4 Cytokine Assay - ELISA 
(A) BD OptEIA ELISA Kit 
Cytokine production (with exception of TNF-α, IL-17 and IL-23) was assayed using BD 
OptEIA ELISA kit according to manufacturer’s instruction. Briefly, 96-well assay 
plated were coated with 100 µl/well of capture antibody diluted in coating buffer and 
incubated overnight at 4 °C. The following day, the plate was aspirated and washed for 
three times with 1 x wash buffer. Blocking was carried out using 200 µl of assay diluent 
for one hour. After washing the plate for three times, 100 µl of standard or sample was 
added to each well and incubated overnight at 4°C. On the next day, the washing step 
was performed five times and 100 µl of working detector (detection antibody and 
Avidin-HRP diluted according to manufacturer’s instruction) was added to each well. 
After two hours of incubation at room temperature, the plate was washed for seven 
times with one minute incubation between washes. Substrate solution containing equal 
volumes of Reagent A and Reagent B was added in volumes of 100 µl to each well. The 
plate was then incubated in dark for 30 minutes at room temperature to allow 
colorimetric development. Finally, the reaction was stopped with 50 µl of Stop solution 
(H2SO4) for each well. Reading of the plates was done using a Bio-rad microplate reader, 
Bio-rad microplate manager model 680, version 5.2 at a wavelength of 450 nm.  
 
(B) R&D ELISA Kit 
The procedure of ELISA for TNF-α and IL-17 was similar to section (A) above with 
some slight modifications according to the manufacturer’s instruction. After the addition 
of standard and sample, the plate was incubated for 3 hours at room temperature instead 
of overnight at 4 °C. The incubation with detection antibody was carried out for 2 hours, 
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washed and continued with the incubation of Avidin-HRP for 30 min. The assay was 
completed on the same day.  
 
(C) eBioscience ELISA Kit 
The procedure of ELISA for IL-23 was performed according to the manufacturer’s 
instruction. Firstly, 96-well assay plated were coated with 100 µl/well of capture 
antibody diluted in PBS, pH 7 and incubated overnight at 4°C. Blocking was done in 
diluent provided in the kit for 1 hr at RT. Cytokine standards and samples were then 
diluted in the same diluent. After the addition of standard and sample, the plate was 
incubated overnight at 4°C. The plate was then incubated with secondary antibody for 1 
hr at RT followed by 30 min of avidin-HRP incubation at RT. Plate was washed with 
washing buffer between each incubation step. TMB substrate (provided with kit) was 
then added to the wells (100 µl each well) for colorimetric development. The reaction 
was stopped with 50 µl of 0.2 N H2SO4 for each well. Reading of the plates was done 
using a Bio-rad microplate reader, Bio-rad microplate manager model 680, version 5.2 
at a wavelength of 450 nm.  
 
2.5 Protein Chemistry and Electrophoresis Tecniques 
2.5.1 SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Table 2.1 Reagents for SDS-PAGE 
 
Reagents Separating 12.5 % Separating 15 %  Stacking 6 % 
ddH2O 3.17 ml 2.35 ml 3.05 ml 
Tris pH 8.8 2.5 ml (pH 8.8) 2.5 ml (pH 8.8) 1.25 ml (pH 6.8) 
10 % SDS 100 µl 100 µl 50 µl 
30 % Acrylamide  4.16 ml 5 ml 0.65 ml 
10 % APS 50 µl 50 µl 25 µl 
TEMED 5 µl 5 µl 5 µl 
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Sodium dodecylsulfate (SDS)   10% (w/v) in H2O 
 
Ammonium Persulfate (APS)    10% (w/v) in H2O 
 
N,N,N’,N-tetramethylene-diamine (TEMED)  
 
Reducing sample buffer (5x)    0.6 ml 1M Tris-HCl, pH 6.8 
       5 ml 50% (v/v) glycerol 
       2 ml10% (w/v) SDS 
       0.1 mM DTT 
       1 ml 1% (w/v) bromophenol blue 
       0.9 ml H2O 
 
Non-reducing sample buffer (5x)   0.6 ml 1M Tris-HCl, pH 6.8 
       5 ml 50% (v/v) glycerol 
       2 ml10% (w/v) SDS 
       1 ml 1% (w/v) bromophenol blue 
       1.4 ml H2O 
 
Electrophoresis Buffer    3g Tris (25 mM) 
       14.4 g glycine (192 mM) 
       1 g SDS (0.1 % w/v) 
       H2O to make 1 litre 
 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) was carried out in a Mini-
Protean III electrophoresis chamber (Bio-rad). Samples were denatured by heating at 
100 °C for 10 min in reducing or non-reducing sample buffer. Electrophoresis was 
conducted at 100 V at RT in electrophoresis buffer. Electrophoresis was stopped when 
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the dye-front had reached the end of the gel. Protein bands were visualized by 
Coomassie Brilliant Blue staining or Silver staining. 
 
2.5.2 Coomassie Brilliant Blue Staining 
Coomassie Brilliant Blue Staining Solution  1 g Coomassie Blue R-250 
 
450 ml methanol  
 
450 ml H2O   
  
100 ml glacial acetic acid 
 
Destaining Solution     10% glacial acetic acid with H2O 
 
 
The gel was transferred to a container with 20 ml of Coomassie staining solution and 
staining was allowed to proceed for 15 min at RT on a shaking platform. The staining 
solution was discarded and the gel was transferred to 50 ml of destaining solution. 
Destaining of gel was carried out until protein bands could be clearly observed. The 
detection limit of Coomassie Brilliant Blue staining is 0.1 µg of protein in a single band. 
 
2.5.3 Silver Staining 
After SDS-PAGE, gel was soaked into 50 ml of 50 % ethanol / 10 % acetic acid for 10 
min and transferred into 50 ml of 5 % ethanol / 7 % acetic acid for another 10 mins. Gel 
was washed with ddH2O for 5 times (2 min each wash). Gel was then soaked in 100 ml 
of ddH2O  with 0.06 mM DTT for 15 min. Gel was wash 5x and transferred to 50 ml of 
0.1 % of AgNO3 (silver nitrate) for 30 min. After 30 mins, the gel was transferred 
immediately to 100 ml of 3 % Na2CO3 supplemented with 50 µl of 37 % formaldehyde 
and soaked for 1 min. The solution was poured away and fresh 100 ml of 3 % Na2CO3 
supplemented with 50 µl of 37 % formaldehyde was added for the development of silver 
stained bands. The staining reaction was monitored until bands were clearly visible and 
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2.4 M of citric acid was added to stop the reaction. All steps were performed at RT on a 
rocking platform. 
 
2.5.4 Quantification of Protein Concentration – Bradford Assay 
Bradford assay was performed according to manufacturer’s (Bio-rad) instruction. 
Briefly, a standard curve ranging from 0-400 µg/ml was constructed. Samples were 
diluted to the working range with H2O. Samples were loaded into a 96-well plate (10 µl 
per well) and 200 µl of 1x Bradford dye was added to each well. The plate was then 
read with a Bio-rad microplate reader, Bio-rad microplate manager model 680, version 
5.2 at 595 nm after 5 min incubation and protein concentration was estimated from the 
absorbance reading and the standard curve. 
 
2.6 Molecular Biology Techniques 
2.6.1 Polymerase Chain Reaction (PCR) 
PCR was performed in 30 µl reaction volumes each containing 10mM Tris-HCl (pH8.8), 
1.5 mM MgCl2, 50 mM KCl, 0.1% (v/v) triton X-100, 200 µM of each dNTP, 0.5 µM of 
each forward and reverse primers and 1.25 U of Taq polymerase (Promega). 
Amplification was carried out in a DNA thermal cycler (MJ research, Inc, Waltham, 
MA) for 30 cycles. Each cycle comprises of 30 seconds at 94°C, 30 seconds at 52-68°C 
and 1-3 minutes at 72°C. At the end of last cycle, the reactions were extended for 10 
minutes at 72°C. The PCR products were analyzed on 1-2% (w/v) agarose gels. The 






Table 2.2 Primers used in PCR 
 
Primers Sequence (5’-3’) 
IL-12p40 F TGCAGTTAGGTTCTGATCCA 
IL-12p40 R CAGCAAAGATATCATTGTGATCCT 
IL-12p35 F TTTACCCTTGCACTTCTGA 
IL-12p35 R CAACTCCCATTAGTTATGAAAGA 
IL-23p19 F AATCAGGCTCAAAGCAAGTG 
IL-23p19 R TCTTCTCTTAGATCCATGTGTCC 
IL-10 F AATGCCTTTAATAAGCTCCAAGA 
IL-10 R TCTCAGTTTCGTATCTTCATTGT 
β-actin F GGAAGGAAGGCTGGAAGA 
β-actin R GGCGTGATGGTGGGCATG 
GAPDH F CGGAGTCAACGGATTTGGTCG 
GAPDH R TCTCGCTCCTGGAAGATGGTGAT 
 
 
2.6.2 Real-time Polymerase Chain Reaction 
Real-time PCR was performed in 20 µl reaction volumes with each containing 10 µl of 
SYBr Green Master Mix (ABI), 2 µl of cDNA, 1 µl of forward and reverse primer and 7 
µl of nuclease-free water. Reaction was carried out in a 7500 Real Time PCR System 





2.6.3 Isolation of Total RNA 
Total RNA of monocytes, macrophages and DCs were isolated using TRIZOL
®
 reagent 
(Gibco, BRL). One million cells were lysed in 1 ml of TRIZOL reagent. The cell lysate 
was allowed to stand at room temperature for five minutes before the addition of 0.2 ml 
chloroform. The mixture was subjected to vigorous mixing for 15 seconds and allowed 
to stand for five minutes. Following, the mixture was centrifuged at 12, 000 rpm for 15 
minutes at 4°C. After centrifugation, the colourless aqueous layer containing RNA was 
transferred into a fresh eppendorf tube. RNA precipitation was carried out using 0.5 ml 
of isopropyl alcohol. After incubation of 10 minutes, the precipitated RNA was 
centrifuged for 10 minutes at 12, 000 rpm. The supernatant was removed after 
centrifugation and the pellet washed with 70 % (v/v) ethanol. The washed RNA was 
allowed to dry and the purified RNA was dissolved in 20 µl of Diethyl Pyrocarbonate 
(DEPC, Sigma)-treated water. Dissolved RNA was stored at -80°C. 
 
2.6.4 Quantification of RNA 
RNA optical density was measured with Nanodrop™ Spectrophotometer ND-1000. The 
readings at 280 nm, 260 nm and 230 nm were taken. The ratio of OD260/OD280 was used 
to determine RNA purity. RNA samples were used in experiments only when the 
OD260/OD280 ratio is greater than 1.8 
 
2.6.5 Reverse Transcription and cDNA synthesis 
Reverse transcription was carried out using the Advantage RT-for-PCR Kit (Clontech 
Laboratories, Palo Alto, CA). Briefly, RNA was diluted to 1 µg/ml in DEPC-treated 
water to a total volume of 12.5 µl. The RNA was mixed with random hexamers and 
oligo(dT)18 primers. The mixture was denatured at 70°C for two minutes and rapidly 
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quenched on ice. Reverse-transcription (RT) was carried out for one hour at 42°C in 20 
µl reactions containing 50 mM Tris-HCl (pH 8.3), 75 mM KCl, 3 mM MgCl2, 0.5 mM 
of each dNTP, 20 U recombinant RNase inhibitor and 200 U moloney murine leukemia 
virus (MMLV) reverse transcriptase. cDNA synthesis was terminated by heating at 
94 °C for five minutes. The synthesized cDNA was either used immediately or stored at 
-80 °C. 
 
2.6.6 DNA Agarose Gel Electrophoresis 
Agarose was melted in Tris-Acetate-EDTA buffer (TAE: 40 mM Tris, 20 mM Acetic 
acid, 1 mM EDTA, pH 7.8) at a concentration of 1 – 2 % (w/v). The melted agarose was 
allowed to cool to approximately 60°C and 0.05 % (v/v) of gel green was added to the 
mixture. The agarose solution was then casted in a gel casting set. DNA samples were 
mixed with a five-fold dilution of five-times (5 x) sample buffer (15 % (w/v) Ficoll 400, 
0.1 M Na2EDTA (pH 8.0), 0.025 % (w/v) bromophenol blue and 0.25 % (w/v) xylene 
cyanol) and loaded into the wells of the gel together with 1 Kb Plus DNA Size Standard 
(Gibco, BRL). Electrophoresis was carried out at 100 V in TAE buffer. Electrophoresis 
was stopped when the dye front had reached ¾ of the gels. Visualization was carried out 
under a UV illuminator. Results were recorded by photography with Chemi-Smart 3000 
Gel Doc Imaging System supported by Chemicapt version 12.6a software (Vilber 








2.7 Histone Study Techniques 
2.7.1 Cell Lysis 
(A) Biosource Lysis Buffer 
Cell lysis was carried out according to manufacturer’s instruction. Phosphatase inhibitor 
and protease inhibitor were added to the 1 x lysis buffer before cell lysis to prevent 
phosphorylation or degradation of proteins. Cell lysis was carried out for 30 min on a 
rotator at 4°C. 
(B) Hypotonic Lysis Buffer 
Hypotonic cell lysis was performed as described by Hake et. al., 2007. Cells were 
harvested on ice and kept on 4 °C for subsequent steps. Cells were washed three times 
with cold PBS and re-suspended at a maximum concentration of 5 x 10
6
 cells / ml of 
hypotonic lysis buffer in a 1.5 ml tube. Cells were incubated for 30 min on a rotator at 
4 °C to promote hypotonic swelling of cells and lysis by mechanical shearing. The 
intact nuclei was pelleted by centrifuging at 10 000 g for 10 min and used for nuclear 
extract preparation. 
 
2.7.2 Acid Extraction of Histones 
Intact nuclei were collected by centrifugation after hypotonic cell lysis. Supernatant was 
discarded and nuclei obtained from each 5 x 10
6
 cells were re-suspended in 400 µl of 
0.4 N H2SO4. Nuclei were then incubation overnight at 4 °C on a rotator. Nuclear debris 
were then removed the next day by centrifugation at 16 000 g, 10 min. The histones will 
be in the supernatant. The supernatant which was highly acidic was dialyzed into ddH2O 





2.7.3 SDS Isolation of Histones 
Cells were cooled quickly to 4 °C and harvested on ice by mechanical scraping. Cells 
were washed three times with cold PBS. At the last wash, cells will be separated into 2 
fractions at a ratio of 1:5. The lesser fraction will be re-suspended with Biosource lysis 
buffer for cell lysis and used to determine the protein concentration. The other fraction 
will be re-suspended with 100 µl of 1x SDS sample buffer (diluted from 5x non-
reducing sample buffer for SDS-PAGE) containing 100 mM DTT. The maximum 
density of cells re-suspended into the sample buffer was 5 x 10
6
 cells / ml. The cells 
were then subjected to 2 cycles of ultra-sonication by a Biorupter (Diagenode Inc., 
Belgium). Each cycle comprised of 30 sec ultra-sonication and 30 sec rest performed at 
4 °C. 
 
2.8 Cell Death Assessment – LDH Assay 
Cell death was assessed by measuring the released levels of endogenous lactate 
dehydrogenase (LDH). The assay was carried out according to the manufacturer’s 
(Pierce, Rockford, IL) instruction. Briefly, cells in 96-well plate (1 x 10
5
 cells per well 
in 100 µl) were centrifuged at 2000 g, 3 min and the supernatant was harvested for the 
assay of LDH levels. A 100 % total LDH control (total cell lysate) was prepared by 
subjecting equal amount of cells to lysis by 1 x lysis buffer (provided in kit). Other 
controls that included were LDH positive control (kit provided), media control (to 
correct for phenol-red present in cell culture media). The assay was performed in 
triplicates with 50 µl of samples, total cell lysate, media control and LDH positive 
control added to the 96-well plate. 50 µl of substrate solution was added to the wells and 
the colorimetric development was allowed to proceed for 30 min. After 30 min, 50 µl of 
stop solution (provided in kit) was added to the wells and the plates were read at an 
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absorbance of 490 nm with a Bio-rad microplate reader, Bio-rad microplate manager 
model 680, version 5.2. Levels of LDH released were determined from the absorbance 
readings as below. 
 Cell death % = (OD490nm of samples - OD490nm of media control)   x 100% 
                                   OD490nm of Total Cell Lysate 
 
 OD490nm of Total Cell Lysate = 100 % 
 
2.9 Stastitical Analysis 








































Dimethyl sulfoxide (DMSO, [(CH3)2SO]) is an amphipathic molecule with a highly 
polar domain and two apolar methyl groups. Hence, DMSO is soluble in both aqueous 
and organic media. This unique property had made DMSO a widely used solvent for the 
administration of water-insoluble-subtances in vivo. The other important characteristic 
of DMSO is that it is a hydrogen–bound disrupter (Santos et al., 1997), making it an 
important chemical in both the laboratory and clinical settings such as its applications as 
cyroprotectant, cell differentiating agent, hydroxyl radical scavenger, intercellular 
electrical uncoupler, intracellular low-density lipoprotein-derived cholesterol mobilizing 
agent, solubilizing agent used in sample preparation for electron microscopy, antidote to 
the extravasation of vesicant anticancer agents, and topical analgesic (Santos et al., 
2003).  
 
DMSO is currently widely used in the storage of cell lines as it is an effective 
cryoprotectant. Nevertheless, DMSO has been known to be toxic to cells at high 
concentrations. Despite its side effects (Zhang and Eyzaguirre, 1999), it offers 
protection to the cryo-preserved cells. (Kubin et al., 1994) reported that DMSO could 
enhance LPS-elicited IL-12 production by human myeloid leukemia cell lines and 
primary peripheral blood mononuclear cells. In vivo, dendritic cells (DCs) are major 
producers of IL-12 which is key to the induction of Th1 type of immunity. In this study, 
we examine how DMSO regulates IL-12 production by DCs. We found that while 
DMSO increases the production of IL-12 by DCs, it suppresses LPS-elicited IL-10 
production by these cells, further potentiating a Th1 immune response. However, 
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DMSO has minimal effect on the phenotype of DCs and T cells. Besides, DMSO also 
polarizes macrophages towards a Th1 immune response though not as prominently as it 
does with DCs. 
 
3.2 Monocytes differentiate into Macrophages and DCs 
The main cell type used in this project is DC with macrophages being included in some 
experiments. Both macrophages and DCs used in this investigation were derived from 
monocytes (Cao et al., 2006). Monocytes were isolated from buffy coat preparations of 
healthy blood donors by an adhesion method. Monocytes but not other blood leukocytes 
adhere to tissue culture plates under defined conditions which allow the separation of 
these cells from other leukocytes (e.g. lymphocytes). Monocytes isolated by this method 
were around 95 % pure as judged by the high levels of surface CD14 molecules. The 
monocytes can be differentiated into three different types of macrophages when cultured 
with different cytokines; (i) MCSF alone, (ii) GMCSF alone, and (iii) MCSF + GMCSF. 
Thus generated macrophages are named M-MF, GM-MF, and MGM-MF, respectively. 
All three macrophage types had high levels of CD14 surface expression and low CD1a 
expression.  
 
M-MF displayed a phenotype characterized by generally weak response to IFN-γ and 
LPS stimulation in term of IL-12 production. However, these cells produced high levels 
of IL-10 when challenged with LPS. GM-MF and MGM-MF produced higher levels of 





Likewise, three types of DCs were generated from monocytes by culturing with (i) 
MCSF + IL-4 (M-DC), (ii) GMCSF + IL-4 (GM-DC) and (iii) MCSF + GMCSF+ IL-4 
(MGM-DC). All three DC types expressed surface CD1a to a significant level but they 
have down-regulated surface expression of CD14. GM-DCs represent a population of 
inflammatory DCs and were able to respond to IFN-γ/LPS treatment by producing high 
levels of IL-12. GM-DCs will be used in most experiments of this study. MGM-DC was 
found to be similar to GM-DC while M-DC was less immunostimulatory compared to 
the other two DC types. M-DCs were poor in IL-12 production but these cells produce a 
significant amount of IL-10 when challenged with LPS. The phenotypic characteristics 



































Figure 3.1 Phenotypic markers on monocytes, macrophages and DCs. Macrophages 
(Mac) shown in this experiment are M-CSF macrophages, DCs are GM-CSF DCs. Two 
surface markers are examined (CD14 and CD1a). After activation with LPS for 24 hr, 
macrophages were also examined for CD54 and DCs examined for surface CD83. 
Activated DCs are also known as mature DC (mDC). Before activation, DCs are also 
known as immature DC (imDCs). Solid histograms represent isotype control; solid lines 
represent surface markers on monocytes (MCs), macrophages and imDCs without LPS 
stimulation. CD54 and CD83 detected on activated macrophages and DCs are 
represented by dotted blue histograms. Cell analysis was performed on FACScalibur 






3.3 DMSO Effect on Cytokine production by Macrophages and DCs 
Macrophages and DCs were cultured under different conditions to generate the six 
different cell types; M-MF, GM-MF, MGM-MF, M-DC, GM-DC and MGM-DC. The 
cells were activated either with LPS alone or with both IFN-γ and LPS. Cells were 
activated with or without DMSO priming. As shown in Figure 3.2 (a), with the 
exception of M-MF, all five cell types responded to DMSO priming with an increased 
IL-12p70 production upon IFN-γ/LPS stimulation. DMSO alone did not induce the 
production of IL-12p70 without subsequent IFN-γ/LPS stimulation. The enhancing 
effect of DMSO was most significant with GM-DCs. GM-MF also showed substantial 
increase in IL-12p70 production upon DMSO priming. M-MFs are poor producers of 
IL-12p70 and showed little IL-12p70 production upon IFN-γ/LPS stimulation with or 
without DMSO priming. M-DCs produced low levels of IL-12p70 compared to the 
other DCs though there is a slight increase in the IL-12p70 production upon DMSO 
priming. This suggests that M-MF and M-DC could be more tolerogenic or suppressive 
in immune responses and might favour either Th2 immune response or tolerance while 
GM-DCs seem to have the potential for inducing Th1 type immune response. 
 
The corresponding IL-10 production by these six cell types are shown in Figure 3.2 (b). 
All three macrophage types especially M-MF and M-DC produced high levels of IL-10 
after LPS stimulation. Additional IFN-γ treatment partially inhibited LPS-elicited IL-10 
production. DMSO priming before LPS or IFN-γ/LPS stimulation suppressed IL-10 
production in all six cell types except M-MF. IL-10 production by the five cell types 
decreased greatly when DMSO was present. However, DMSO priming did not result in 
a significant decrease in LPS-elicited IL-10 production by M-MF. M-MF only showed a 
significant decrease in its IL-10 production when M-MF was primed with DMSO and 
87 
 
subsequently challenged with IFN-γ and LPS suggesting that DMSO synergizes with 
IFN-γ to skew the cytokine profile of M-MF. For the other five cell types, DMSO 

























































Figure 3.2 DMSO enhances LPS-elicited IL-12p70 production but suppresses LPS-
elicited IL-10 production. (a) DMSO priming increases the IFN-γ and LPS-elicited IL-
12p70 production by GM-MF, GM-DC and MGM-DC. Cells were primed with DMSO 
(1%) for 12 hr and then stimulated for 24 hr with IFN-γ/LPS. IL-12p70 production was 
measure by ELISA. The increase is most significant in GM-DC. (b) DMSO priming 
caused reduced IL-10 production in all cell types except M-MF. Data shown is a 




























































3.4 Time and Concentration Dependent Effect on DMSO on DCs 
The response of DCs to DMSO treatment was tested under various concentrations and 
under different time periods. A range of DMSO concentrations from 0 to 2 % (v/v) were 
used to prime DCs before subsequent IFN-γ and LPS stimulation. Cytokine production 
especially IL-12p70 was determined. Besides varying the DMSO concentration, the 
duration of DMSO priming was also investigated. Three different time points were 
selected; i.e. 12 hr, 1.5 hr and 0 hr. 0 hr means that DMSO was added to the cells 
immediately before IFN-γ and LPS stimulation. As shown in Figure 3.3a, DMSO at 1 % 
greatly enhanced LPS induction of IL-12p70 from GM-DCs and this was observed 
irrespective of the period of priming, i.e. 0 hr, 1.5 hr or 12 hr. IL-12p70 induction by 
IFN-γ and LPS increased in a dose-dependent manner when priming DMSO 
concentration was increased from 0 to 1 % (Figure 3.3b). However, a sharp decrease in 
IL-12p70 production by GM-DCs was observed at 2 % priming DMSO concentration 
for both LPS and IFN-γ/LPS stimulation. This might be due to DMSO toxicity to DCs 




























































Figure 3.3 DMSO increased IL-12p70 production by GM-DCs in a dose- and time-
dependent manner (a) DCs were primed with DMSO at various concentrations (0 to 
2 %) and for 0 hr, 1.5 hr or 12 hr before LPS stimulation for 24 hr. (b) DCs were primed 
with DMSO at various concentrations (0 to 2 %) and for 0 hr, 1.5hr or 12 hr before IFN-
γ/LPS stimulation for 24 hr.  IL-10 production was assayed by ELISA. Data shown is a 



































































Figure 3.4 illustrates IL-10 production by GM-DCs with DMSO priming for 0 hr, 1.5 hr 
or 12 hr at 0 - 1.0% which were then stimulated with IFN-γ/LPS for another 24 hr. As 
opposed to DMSO-induced increase in IL-12p70 production, DMSO inhibited IL-10 
production by LPS-activated GM-DCs in a dose-dependent manner. The levels of IL-10 
production by IFN-γ/LPS treated GM-DCs also decreased when these cells were primed 
with DMSO (Figure 3.4 (b)). The decrease also showed a dose-dependent manner 
though IFN-γ alone suppressed the overall IL-10 production. Both enhancement of IL-
12p70 production and suppression of IL-10 production by DMSO were most significant 
when 1 % DMSO was used to prime the cells. Hence, DMSO 1 % priming for 1.5 hr 
was chosen for most subsequent experiments unless otherwise stated. For the control 
experiments, cells were primed with DMSO at the corresponding DMSO concentrations 
























































Figure 3.4 DMSO inhibits IL-10 production by GM-DCs in a dose- and time-
dependent manner DCs were primed with DMSO at various concentrations (0 to 2 %) 
and for 0 hr, 1.5 hr or 12 hr before LPS stimulation for another 24 hr. IL-12p70 (a) and 



























































3.5 DMSO Treatment Effect on Cell Survival 
Lactate dehydrogenase (LDH) is an intracellular enzyme that will only be released upon 
cell death. LDH levels were measured to determine the extent of cell death in these 
experiments which can also affect IL-12p70 and IL-10 production. Figure 3.5 (a) shows 
the level of cell death in GM-DC culture when the cells were primed with different 
concentrations of DMSO for 12 hr, 1.5 hr or 0 hr. GM-DC was also stimulated with 
IFN-γ/LPS after DMSO priming. DMSO priming up to 1 % did not significantly 
increase cell death as judged from the levels of LDH released. However, elevated LDH 
release was seen in the cell culture upon priming at 2 % DMSO. This could be the 
reason why DC primed at 2 % DMSO failed to produce IL-12p70 and IL-10 as shown 
in Figure 3.4. 
 
Figure 3.5 (b) showed that LDH levels in the GM-DC culture were similar with or 
without DMSO 1 % priming. This suggests that DMSO has minimal toxicity on the 
DCs used in this study as the level of cell death indicated by the level of LDH released 
is similar regardless of the presence or absence of DMSO. The LDH levels decreased 
substantially when DMSO was removed by washing before IFN-γ/LPS stimulation. The 
washing of cells is to remove the DMSO from the culture supernatant. This was to 
investigate if the continuous presence of DMSO would result in a higher percentage of 
cells death. However, the levels of LDH released were similar for both control and 
DMSO 1% DCs. The LDH levels measured were relative to the total amount of LDH 
released upon complete lysis of GM-DCs (Total Cell Lysate). Figure 3.5(b) also 










































Figure 3.5 Determination of DMSO toxicity by LDH release assay. (a) LDH levels 
were measured to determine extent of cell death upon treatment by DMSO at various 
concentrations and durations. GM-DCs showed signs of toxicity upon 2 % DMSO 
priming. (b) DMSO 1 % was removed by washing prior to IFN-γ/LPS treatment. Cell 
viability was higher when DMSO was removed through washing. Data shown is a 






























































3.6 DMSO Effect on Cytokine Production by GM-DC is reversible 
DMSO at 1% greatly enhanced IL-12p70 production by IFN-γ/LPS-stimulated GM-DCs. 
It was shown in Figure 3.6(a) that removing of DMSO by washing before IFN-γ/ LPS 
stimulation, also removed the enhancement effect of DMSO on IFN-γ/LPS-elicited IL-
12p70 production in GM-DC. . The increase in IL-12p70 production by GM-DCs, 
which were primed with DMSO 1 % and then washed, was negligible compared to GM-
DCs which were not primed with DMSO. It shows that the synergistic effect of DMSO 
requires its constant co-stimulation.   
 
Similarly, the DMSO effect on IL-10 production was also lost upon the removal of 
DMSO. DMSO significantly reduced the production of IL-10 by LPS-stimulated GM-
DCs. IFN-γ alone also down-regulated LPS-elicited IL-10 production. Figure 3.6(b) 
demonstrated that, if DMSO was removed before LPS stimulation, LPS-elicited IL-10 
production by GM-DCs was not affected. DMSO synergized with IFN-γ to suppress 
LPS-elicited IL-10 production further to near background level. Thus, DMSO can 
potentially skew immune response towards a Th1 type of immune response by 
increasing IL-12p70 production while suppressing IL-10 production. Nevertheless, 
DMSO is only able to exert its influence when it co-exists with microbial or 
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Figure 3.6 DMSO effect on cytokine by GM-DCS is lost upon removal of DMSO. 
Cells were primed with 1 % DMSO for 2 hr before washing with medium to removed 
DMSO from the culture which was followed by IFN-γ/LPS stimulation. (a) The 
enhancement of LPS or IFN-γ/LPS-elicited IL-12p70 by DMSO diminished upon 
removal of DMSO. (b) DMSO was not able to inhibit LPS-elicited IL-10 production by 
GM-DCs if it is removed from the culture media before LPS stimulation. Data shown is 
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3.7 DMSO Effect on GM-DC Maturation 
Figure 3.7 shows the surface molecules on DCs which are indicative of immature GM-
DCs and activated or mature DCs. DCs were activated with IFN-γ/LPS with or without 
prior DMSO priming. Immature GM-DCs typically express low levels of surface CD14, 
high levels of surface CD1a, and high levels of surface MHC II molecules. After IFN-
γ/LPS activation, the expression of CD14 and CD1a remains the same. Figure 3.7(a) 
shows that DMSO (1 %) treatment did not alter the expression of these surface 
molecules on GM-DCs. Hence, DMSO treatment has not changed these two 
characteristic surface markers on GM-DCs. 
 
Matured GM-DCs exhibited increased surface expression of MHC II, CD86, CD80 and 
CD83. Figure 3.7(b) shows that the expression of CD86, CD83 and CD80 on GM-DCs 
was low before activation. However, GM-DCs activated with IFN-γ/LPS showed a 
significant up-regulation. Immature GM-DCs already expressed high MHC II but this 
was further elevated upon activation. Nevertheless, DMSO priming had no significant 
effect on the surface expression of these activation markers. Immature GM-DCs that 
were primed with 1 % DMSO alone showed no significant change in the expression of 
these molecules GM-DCs that were primed with DMSO and then stimulated with IFN-
γ/LPS showed levels of these molecules as compared to IFN-γ/LPS-activated GM-DCs 
which were not primed with DMSO. Therefore, DMSO priming did not alter the surface 
and activation markers of GM-DCs leaving its regulation of GM-DCs selectively in the 











































Figure 3.7 DMSO does not alter expression of cell surface markers. (a) GM-DCs 
primed with DMSO at 1% displayed no difference in the expression of CD14 and CD1a. 
(b) Surface expression of CD80, CD86, CD83 and MHC II on imDCs and IFN-γ/LPS-
activated DCs was not affected by DMSO (1 %) priming. No significant up-regulation 
of DC activation markers was observed upon DMSO priming. Clear region represents 
isotype control while green shaded region represents the test antibody marker. Data 


















































































































































































































































































































DMSO Effect on Cell Surface Markers
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3.8 DMSO does not Affect the Morphology of DCs 
Figure 3.7 demonstrates that DMSO priming did not alter the expression of surface 
molecules on GM-DCs. The morphology of GM-DCs was examined for changes 
induced by DMSO priming. As shown in Figure 3.8, imDCs appear as tiny clusters in 
culture under microscope with slight projections of dendrites. Upon IFN-γ/LPS 
stimulation, imDCs become mature mDCs displaying many dendrite projections inter-
connecting the different cell clusters. mDCs also appear to have great motility. DMSO-
primed   imDCs and mDCs showed no significant change in this characteristic DC 
morphology though imDCs primed with DMSO for 24 hr appeared to have more 
clustered cells in the culture. Similarly, DMSO-primed mDCs had large amount of 
dendrite projections and was not significantly different from mDCs without DMSO 
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Figure 3.8 DMSO does not affect GM-DC morphology Immature GM-DCs (a), 
DMSO (1%)-primed GM-DCs (b), IFN-γ/LPS-stimulated GM-DCs without DMSO 
priming (c), and IFN-γ/LPS-stimulated GM-DCs with DMSO priming (d) were 











3.9 DMSO Enhances Th1 Type Immune Response induced by GM-DC 
GM-DCs were primed with DMSO for 2 hr and subsequently stimulated with IFN-
γ/LPS for another 24 hours before RNA isolation. Real-time PCR was performed to 
determine cytokine regulation by DMSO at the transcriptional level. The culture 
supernatants from the same experiments were collected and assayed for cytokine 
production by ELISA. The mRNA for IL-12p40 and IL-12p35, two subunits that form 
the bioactive IL-12p70, was determined. Results showed that GM-DCs produced large 
amounts of IL-12p40 and IL-12p35 mRNA when stimulated with IFN-γ/LPS (Figure 
3.9a and 3.9b). DMSO priming alone did not affect the RNA expression for IL-12p40 
and IL-12p35. However, when GM-DCs were first primed with DMSO and 
subsequently stimulated with IFN-γ/LPS, a significant increase in IL-12p40 and IL-
12p35 mRNA expression was observed. This is consistent with the ELISA result. 
(Figure 3.10a and 3.10b). GM-DCs produced IL-12p70 upon IFN-γ/LPS stimulation. 
DMSO (1 %) priming before IFN-γ/LPS stimulation greatly increased IL-12p70 
induction. DMSO priming alone did not result in IL-12p70 production by GM-DCs. 
Similarly, IFN-γ/LPS-elicited IL-12p40 production was increased when GM-DCs were 
primed with DMSO.  
 
Figure 3.9(c) shows that GM-DCs also produced high amount of IL-23p19 if these cells 
were primed with DMSO before stimulation with IFN-γ/LPS. IL-23p19 is a subunit of 
IL-23 and the other subunit for this cytokine is IL-12p40. IFN-γ/LPS induced much less 
IL-23p19 mRNA from GM-DCs without DMSO priming. Figure 3.10(c) shows that 
IFN-γ/LPS indeed increased much higher levels of IL-23 in DMSO primed GM-DCs as 
compared to GM-DCs without DMSO priming.  
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Analysis of real-time PCR results showed that DMSO slightly decreases the mRNA of 
IL-10 mRNA in GM-DCs (Figure 3.9d). However, IFN-γ seems to play a greater role 
than DMSO in inhibiting LPS-elicited IL-10 mRNA expression. Figure 3.10(d) showed 
that IL-10 cytokine was much reduced in culture with DMSO-primed GM-DCs upon 
IFN-γ/LPS stimulation, as compared to activated GM-DCs without DMSO priming. It 
was noted that the IL-10 mRNA was present in GM-DCs without stimulation but no IL-
10 was secreted by these cells. IL-10 cytokine was only produced when GM-DCs were 
stimulated with IFN-γ/LPS.  The PCR product was also analyzed on a 1% agarose gel. 
The results are shown in the gel photo in Figure 3.9e. The brightness of the DNA bands 
correspond to the levels of real-time PCR. 
 
Thus, both the real-time PCR and ELISA results, especially the latter, indicate that 
DMSO skews GM-DCs for the induction of Th1 type of immune response. The reduced 
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Figure 3.9 Real-time PCR detection of cytokine mRNA in DMSO-primed GM-DCs. 
GM-DCs were treated as follows: (1) unstimulated (neg), (2) stimulated for 24 hr with 
IFN-γ/LPS, (3) stimulated with DMSO for 2 hr, AND (4) primed with DMSO for 2 hr 
followed by IFN-γ/LPS stimulation for 24 hr. RNA was isolated from these cells for 
RT-PCR detection of mRNA for IL-12p40 (a), IL-12p35 (b), IL-23p19 (c), and IL-10 
(d). DMSO priming increased IL-12p40, IL-12p35 and IL-23p19 mRNA expression but 
it inhibited IL-10 (d) mRNA expression. IFN-γ also inhibited IL-10 mRNA expression. 
(e) The RT-PCR reactions were also examined on a 1% agarose gel (Lane 1,Control; 
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Figure 3.10 DMSO regulation of DC cytokine production. After cells were harvested 
for RNA isolation, the culture supernatants were used for ELISA detection of (a) IL-


























































































Figure 3.10 DMSO regulation of DC cytokine production. After cells were harvested 
for RNA isolation, the culture supernatants were used for ELISA detection of (a) IL-






















































3.10 DMSO Effect on Histone Expression and Histone Modifications on DCs 
How DMSO synergizes with IFN-γ/LPS in IL-12p70, and IL-23 induction while 
inhibiting IL-10 induction from GM-DCs is not understood. Examination of DMSO on 
IFN-γ/LPS -elicited ERK, p38 and PI3K signaling revealed no obvious effect (data not 
shown). We then asked whether DMSO synergizes through epigenetic regulation 
through chromatin modification by examining the methylation, phosphorylation and 
acetylation status of histone 3 (H3).  
 
Figure 3.11 shows the panel of histone H3 modifications investigated. For simplicity, 
abbreviated names are used in this section for untreated GM-DCs (con-DC), DMSO 
primed-GM-DCs (DMSO-DC), IFN-γ/LPS-stimulated GM-DCs (IL-DC) and IFN-
γ/LPS-treated GM-DCs with DMSO priming (DIL-DC). The expression level of histone 
H3 was not affected by IFN-γ/LPS or DMSO stimulation. Methylation of H3 on 5 
different lysine residues were examined. Dimethylation on lysine 4 (H3K4me2) was 
high in GM-DCs and this was not affected by DMSO or/and IFN-γ/LPS stimulation. 
IFN-γ/LPS slightly inhibited dimethylation on lysine 9 (H3K9me2) but this was rescued 
by DMSO which, by itself, significantly increased lysine 9 dimethylation. DMSO was 
found to marginally increase the dimethylation of lysine 27 (H3K27me2) while it 
reduced the IFN-γ/LPS-induced increase in the dimethylation of lysine 36 (H3K36me2) 
and lysine 79 (H3K79me2) to levels that were not different from that observed in 
untreated GM-DCs. Overall, synergy between DMSO and IFN-γ/LPS in the regulation 
of H3 methylation was not obvious except for lysine 9 where it was consistenly noted 




H3 acetylation was examined on lysine 18, 23 and 28. Lysine 18 is highly acetylated in 
unstimulated GM-DCs (H3K18Ac) and this was not affected by DMSO or IFN-γ/LPS. 
In contrast, both lysine 23 and 28 showed low acetylation and these were not affected 
by DMSO or IFN-γ/LPS. Lysine 9 is a versatile residue which, beside methylation, is 
also acetylated. Acetylated lysine 9 can be detected in conjunction with phosphorylated 
serine 10 residue using a single antibody. In unstimulated GM-DCs, this double 
modification (H3S10PK9Ac) was strong but this was inhibited by both IFN-γ/LPS and 
DMSO to the same extents However, synergy between these two stimuli was not 
observed in inhibiting this double modification. 
 
Phosphorylation on threonine 3 and 11 was also examined on H3. Unstimulated GM-
DCs showed a high level of threonine 3 phosphorylation (H3Thr3P). However, this was 
markedly reduced upon IFN-γ/LPS or DMSO stimulation. Synergy was again not 
observed between IFN-γ/LPS and DMSO in inhibiting threonine 3 phosphorylation. 
Phosphorylation of threonine 11 (H3Thr11P) was low in GM-DCs and was not 
significantly altered by the stimuli. The expression of human β-actin was detected to 



















Control     IL   DMSO   DIL
Legend:
D – DMSO (1%)
I – IFN-γ (500 ng/ml)








IL – IFN-γ + LPS




Figure 3.11 Western blot analysis of DMSO- and IFN-g/LPS-induced  histone H3 
methylation, acetylation and phosphorylation in GM-DCs. DMSO priming did 
affect some H3 modifications but synergy was observed between DMSO and IFN-
γ/LPS to explain the synergy observed in the induction of IL-12p70 and IL-23 and in the 
inhibition of IL-10. IL denotes cells stimulated with IFN-γ and LPS while DIL denotes 
cells that were primed with DMSO and further stimulated with IFN-γ and LPS. Data 










3.11 DMSO Effect on CD4
+
 T Cell  
The effect of DMSO on DC production of IL-12, IL-23 and IL-10 is indicative of its 
effect on T cell activation or the activation of adaptive immunity. IL-12 production by 
DC is important for the induction of Th1 cells and IL-23 induces Th17 cells. We 
therefore decide to examine whether DMSO-treated DCs activate these T cell subsets 
differently from the non-primed DCs. This will be examined by mixed leukocyte 
reactions (MLR) by co-culturing DCs with allogeneic CD4
+
 T cells.  
 
Before the MLR experiments, we evaluated whether DMSO has direct stimulatory or 
inhibitory effects on CD4
+
 T cells in the absence of DCs. This was performed by 
activation of CD4
+
 T cells in vitro with anti-CD3 and anti-CD28 antibodies in the 
presence or absence of DMSO. The antibodies were coated on latex beads to stimulate 
naïve CD4
+
 T cells in the presence and absence of DMSO. Culture supernatants were 
harvested and were assayed for IFN-γ, IL-17 and IL-2 production after 3 days and 7 
days. Figure 3.12 shows the cytokine (IFN-γ, IL-17 and IL-2) production by the CD4
+
 T 
cells. DMSO inhibited the production of all three cytokines induced by anti-CD3/anti-
CD28. IFN-γ production was inhibited by more than 50 % in the presence of DMSO 
(Figure 3.12(a)). DMSO almost completely abrogated the production of IL-17 at both 
day 3 and day 7 (Figure 3.12(b)). In Figure 3.12c, it was observed that IL-2 production 
detected in the supernatant collected on day 3 but not that obtained on day 7. 
Nevertheless, DMSO strongly inhibited the production of IL-2 by the activated CD4
+
 T 
cells. These results suggest that, where DMSO is used as a solvent for T cell-stimulating 
agent, its concentration needs to be tightly monitored to avoid the potent inhibitory 
effects. It also presents a challenge in our following up MLR experiments in which 
DMSO is used in the DC-T cell co-culture. 
110 
 



























                                                       















Figure 3.12. Direct DMSO Effect on T Cell Activation. CD4
+
 T cells were primed 
with DMSO for 2 hr before stimulation with anti-CD3/anti-CD28 antibodies coated on 
latex beads. At day 3 and day 7, the culture media were assayed for the production of 
cytokines: (a) IFN-γ; (b) IL-17; and (c) IL-2. Data shown is a representative of 3 
experiments. * p-value < 0.01 










































































3.12 DMSO Effect on Cytokine Production by CD4
+
 T Cells in MLR 
MLR was then performed to investigate how DMSO-primed GM-DCs activate CD4
+
 T 
cells. This was determined by CD4
+
 T cell production of IFN-γ, IL-17 and IL-2 in these 
experiments. As shown in Figure 3.13(a), DMSO alone had no effect on CD4
+
 T cells in 
cytokine production if these cells were not stimulated with DCs or IFN-γ/LPS. However, 
it showed inhibition when these T cells were activated with IFN-γ/LPS. When DCs 
were also present as allogeneic stimuli, the inhibitory effects of DMSO on T cells were 
abolished. While DMSO was previously shown to be potent in increasing GM-DC 
production of IL-12p70, this was not translated into increase of IFN-γ induction in these 
MLR experiments. A possible explanation is that its direct inhibitory effects on T cell 
production of IFN-γ neutralized its indirect stimulatory effects through DCs.  
 
Figure 3.13(b) shows the IL-17 production by CD4
+
 T cells. IFN-γ/LPS stimulated GM-
DCs co-cultured with CD4
+
 T cells had lesser IL-17 production compared to LPS 
activated GM-DCs co-cultured with CD4+ T cells. This is because IFN-γ would skew 
the immune response toward a Th1 type of immune response instead of a Th17 response 
which is usually characterized by the production of IL-17. IL-17 production was greatly 
suppressed when GM-DCs were co-cultured with CD4
+
 T cells in the presence of 
DMSO. From Figure 3.13(c), it was observed that IL-2 production level was very low 
for all experimental conditions though IFN-γ/LPS treatment increased the IL-2 
production. DMSO did not seem to have any effect on the IL-2 production by CD4+ T 
cells in MLR. Therefore, DMSO did not have any significant effect on the 7 days mixed 




Supernatant was removed after seven days for MLR and the CD4
+
 T cells were re-
stimulated with anti-CD3/anti-CD28 coated beads for another 3 days in fresh HI-RPMI. 
Supernatant was harvested and assayed for IFN-γ, IL-17 and IL-2 production. Figure 
3.14(a) showed that upon re-stimulation, the addition of DMSO did not affect IFN-γ 
production for both GM-DCs-CD4
+
 T cells co-cultured and CD4
+
 T cells alone. DMSO 
decreases the IL-17 production levels for both GM-DC-CD4
+
 T cells co-culture and T 
cells alone (Figure 3.14(b)). IL-2 production by re-stimulated CD4
+
 T cells was not 
affected by the presence of DMSO in the co-culture system. These seems to further 
confirm that while DMSO was able to exert significant effect in modulating the 
cytokine profile of antigen presenting cells, DMSO does not affect the activation of 
CD4
+

























































Figure 3.13 DMSO Effect on T Cells Activation (a) DMSO did not induce any 
changes in IFN-γ production in a co-culture system (b) IL-17 production was not 
affected by DMSO but was decreased when IFN-γ was present (c) No significant 
differences in the IL-2 production by T Cells was observed. Data shown is a 
representative of 5 experiments.  
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Figure 3.14 DMSO Effect on T Cells Activation (Re-stimulation) (a) IFN-γ 
production was not affected by DMSO after re-stimulation. (b) IL-17 production by T 
Cells was slightly decreased when cells were primed with DMSO. (c) IL-2 production 
by T Cells upon re-stimulation for 48 hr after 7 days MLR showed no differences. Data 
shown is a representative of 3 experiments.  
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3.13 DMSO Effect on Cytokine Production by CD4
+
 T Cells in Intracellular 
Cytokine Production 
The intracellular pool of cytokines (IFN-γ and IL-17) was studied in a system where 
CD4
+
 T cells were co-cultured with GM-DCs in the presence or absence of DMSO. 
After seven days of co-culture MLR, cells were washed and re-stimulated with 
ionomycin and treated with brefeldin A to prevent secretion of the cytokines produced. 
In Figure 3.15, DMSO increased the intracellular IFN-γ production by CD4
+
 T cells. 
However, DMSO did not increase the intracellular IFN-γ production when GM-DCs 
were co-cultured with CD4
+
 T cells in the presence of DMSO. In fact, DMSO decreased 
the intracellular IFN-γ production compared to GM-DCs co-cultured with CD4+ T cells 


















Figure 3.15 DMSO effect on IFN-γ and IL-17 production by CD4+ T cells 
(Intracellular cytokine staining). Intracellular staining of IFN-γ and IL-17 on GM-
DCs that were co-cultured with CD4+ T cells over seven days. Cells were primed with 
DMSO and stimulated with IFN-γ and LPS. DMSO has no effect on the production of 
IL-17 but increased the IFN-γ production only when GM-DCs were not stimulated with 
DMSO. The vertical axis shows the expression levels of IL-17 while expression levels 















































































































































































































































































































CHAPTER 4 DISCUSSION 
 
4.1 DMSO primes APCs towards a Type I Immune Response 
DMSO is commonly used in the cryo-preservation of cell lines despite its known 
toxicity. There had been various studies on how DMSO cryo-preservation affects the 
cellular function, morphology or characteristics. DMSO has been reported to possess 
various effects on the regulation of inflammation process. One study on human blood 
showed that DMSO inhibited IL-8 production at the transcriptional level and prevents 
neutrophil adhesion to the endothelium (DeForge et. al., 1992). DMSO was also shown 
to be responsible for the decrease of NF-κB activation and TNF-α bio-activity in 
macrophage-like cell line (Kelly et al., 1994). Besides, DMSO has been reported to 
inhibit TNF-α induced-IL-6 production in airway epithelial cells and lung fibroblast 
(Yoshida et. al., 1999), favouring a type one immunity.  
 
This study showed that DMSO primed-IFN-γ/LPS stimulated cells were skewed 
towards a Th1 type of immune response. Three different macrophage types and three 
different DC types were used for this investigation and with the exception of M-MF, the 
other five cell types responded with an increase in LPS-elicited IL-12p70 production. 
GM-DC had the most significant increase of IL-12p70 production as GM-DCs are 
known to be potent APCs in the activation of T cell responses. On the other hand, the 
LPS-elicited IL-10 production for all DMSO primed cells was suppressed significantly 
with the same exception of M-MF which retained its high IL-10 production. IFN-γ too 
was efficient in suppressing the LPS elicited IL-10 production. The suppression of IL-
10 production by IFN-γ had previously been reported by (Dieu-Nosjean et. al., 2001) 
through studies on langerhans cells development.  The DMSO regulation of IL-12 
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production had been previously reported by studies on human myeloid leukemia cell 
line, HL-60 and peripheral blood mononuclear cells (Kubin et al., 1994). This study 
agrees that DMSO is able to regulate IL-12 production and further shows that this 
regulation is found on both macrophages and DCs with DCs demonstrating a stronger 
response to DMSO regulation of IL-12. Till date there are not many studies on the 
regulation of IL-12 by DMSO. In the study by (Kubin et. al., 1994), DMSO was also 
shown to regulate the production of TNF-α and IL-1β.  
 
IFN-γ is produced by NK cells and T cells during infections and acts as a potent 
activator of phagoycytes (Chan et. al., 1991) IFN-γ/LPS stimulates phagocytes to 
produce IL-12. DMSO priming before IFN-γ/LPS stimulation was found to further 
increase the LPS-elicited production of IL-12. DMSO alone was not able to induce any 
IL-12p70 production by macrophages or DCs though the study by Kubin showed that 
DMSO alone was able to induce IL-12p70 production in THP-1 and HL-60. The ability 
of DMSO to synergize with IFN-γ in elevating IL-12 production suggests that DMSO 
might be potent in skewing the immune response towards a Th1 type immune response. 
On the other hand, the suppression of IL-10 production by DMSO suggests the role of 
DMSO being a potent Th1 type immune response inducer as IL-10 possesses an 
antagonistic effect on IL-12 production (Cao et. al., 2002). This further indicates that 
DMSO is able to skew the APCs towards a Th1 type immune response phenotype.  
 
The ability of DMSO in favouring a Th1 type of immune response suggests the 
potential of DMSO as a drug for cancer treatment or as an adjuvant for vaccination. 
DMSO has already been studied for its possible use in cancer treatment as DMSO has 
excellent antioxidant properties (Salim et. al., 1992) and was found to be able to 
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increase the immune recognition of H-2 antigen in H-2 deficient murine lung carcinoma 
(Bahler and Lord, 1985).  
 
4.2 DMSO effect is concentration dependent 
A titration of DMSO concentration from 0 to 2 % was performed to investigate if cells 
were sensitive to DMSO toxicity and the effect of DMSO concentration in regulating 
IL-12 production. Results showed that there was no cytokine production at 2 % DMSO 
concentration possibly due to DMSO toxicity at such high concentration resulting in cell 
death. However, it is worth noting that cell lines are commonly cryo-preserved at 10% 
DMSO which is much higher than the 2% DMSO used in this study. Yet, many studies 
had shown that cryo-preservation of cells at 10% DMSO did not result in significant cell 
death of damage to the cells (Birkeland, 1976; Strong et. al., 1975). The difference 
however, was that the cells were incubated at 37°C for 2 to 24 hours while cryo-
preserved cells are stored at sub-zero temperature in liquid nitrogen. DMSO priming 
was performed either 12 hours, 1.5 hours or just before the addition of LPS or IFN-
γ/LPS. There was no DMSO priming in the control cells. The LPS-elicited IL-12p70 
production increased significantly upon 1% DMSO priming but other concentrations 
were not as effective in increasing the LPS-elicited IL-12p70 production. IL-12p70 
production by IFN-γ/LPS stimulated DCs increased accordingly with the increasing 
DMSO concentrations with the exception of 2 % DMSO. The increasing concentration 
of DMSO corresponded to a gradual inhibition of IL-10 production by DCs. Hence, 
DMSO 1 % was selected to perform most of the subsequent studies. There were no 
significant differences in cytokine production by DCs for the different duration used in 
DMSO priming. This may be due to the supernatant harvested 24 hour later, at the 
saturation point of the cytokine production. Studies from other groups have also chosen 
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a similar range of DMSO concentration (1 – 1.25 %) for their studies (Kubin et. al., 
1994; Trayner et. al., 1998) 
 
4.3 DMSO does not affect cell survival 
DMSO toxicity has been a subject of interest to many because of the potential of DMSO 
as a pain reliever, anti-inflammatory drug and cancer treatment. DMSO toxicity has 
been debated many years. DMSO was claimed to be abe to penetrate the sin without 
causing much damage (Kolb et. al., 1967). However, DMSO toxicity has been observed 
in the study of inflammation, cell cycle, differentiation, lipid metabolism and apoptosis. 
Previous reports suggested that DMSO potentiates TNF-α-induced cytotoxicity in 
various human cell lines (McConnell et. al., 1999) and inihibits IL-8 production 
(DeForge et. al., 1992). DMSO had also been found to inhibit c-myc expression 
resulting in the arrest of cell cycle (Thomas et. al., 1995; Srinivas et. al., 1991; Sawai et. 
al., 1990). In addition, there are reports on DMSO toxicity in lipid metabolism 
especially in the metabolism and transport of cholesterol (Sakuragawa, 1995; Mackie et. 
al., 1989).  
 
DMSO is currently the standard agent for cryo-preservation of cells. (Bӧck et. al., 1995) 




 and lactate dehydrogenase (LDH) 
from the intracellular space into extracellular space while activating the complement 
system in cryo-preserved human platelets. LDH is an enzyme release by the cells upon 
cell death and is commonly used to measure the degree of cell death. In our study, there 
were no cytokine production by DCs when treated with 2% DMSO before LPS and 
IFN-γ challenge. This suggests the possibility that DMSO at 2 % concentration was too 
toxic for cell survival. This study showed that LDH release from DCs were significantly 
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higher at 2 % DMSO compared to the other lower concentrations but the LDH levels for 
2 % DMSO was only 50% of the positive control where all cells were induced to 
apoptosis. This suggests that only 50% of DC cell death occurred at 2 % DMSO.  
Therefore, it appears that DCs are able to survive up to 2 % or maybe higher 
concentration of DMSO (Birkeland, 1976) though there is a possibility of compromise 
in the cellular or immunological functions. Hence, cells cryo-preserved at 10 % DMSO 
would most probably survive but whether its cellular functions remain healthy is 
uncertain. Much further studies will be required to ascertain the long term effects of 
DMSO. 
 
4.4 DMSO does not affect cell morphology and DC maturation 
This study proceeded to investigate if DMSO affects cellular morphology or since it did 
not cause significant cell death while modulating the cytokine production in DCs. The 
addition of DMSO to monocyte derived–DCs did not induce any noticeable changes in 
morphology observed under microscope. Both im-DCs and IFN-γ/LPS activated DCs 
showed no difference in morphology whether with or without DMSO priming. This 
again shows that DMSO is a good cryo-preservation agent as it will not cause 
morphological changes to the cells and thus affect in vitro studies of cell culture.  
 
Changes in antigen expression had been observed on HL-60 cells differentiated with 
DMSO (Trayner et. al., 1998). HL-60 cells can be induced to differentiate into 
neutrophil-like cells by DMSO. Upon differentiation, changes in antigenic expression 
on HL-60 such as CD15, CD63 and CD71 were observed. The authors also noted that 
most changes in antigen expression do not correspond to morphological differentiation. 
Further investigation on the antigen expression on the monocyte-derived DCs upon 
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DMSO treatment was carried out since there were no morphological changes detected. 
Maturation markers CD80, CD83 and CD86 for DCs were included to ascertain if 
DMSO interferes with the maturation process of DCs.  There were no detectable 
changes in the expression of CD14, CD1a and MHC II molecules for imDCs and IFN-
γ/LPS-activated DCs when primed with DMSO for 12 hours. The DCs were then 
activated with IFN-γ/LPS in the presence and absence of DMSO. There were no 
difference observable between DMSO primed and normal IFN-γ/LPS stimulated DCs. 
The expression levels of CD83, CD80 and CD86 remained the same. DMSO primed im-
DCs showed an up-regulation of CD83 expression in comparison to the control im-DCs. 
However, the up-regulation was not as significant compared to the IFN-γ/LPS activated-
DCs. CD86 and CD80 expression on im-DCs were not affected by the presence of 
DMSO. Hence, it appears that DMSO alone is not sufficient to induce the maturation of 
imDCs. DMSO also does not appear to interfere with the maturation process of DCs 
induced by IFN-γ and LPS.  
 
Thus, DMSO is an effective and safe cryo-preservation agent as the DCs seem to be 
able to retain the morphology and antigen expression after DMSO treatment. 
 
4.5 DMSO Effect on cells is reversible 
An experiment was carried out to determine if the continuous presence of DMSO is 
needed to observe the regulation of cytokine production in DCs and macrophages. 
Monocyte derived GM-DCs were primed with 1 % DMSO for 12 hours IFN-γ/LPS 
stimulation. After 12 hours of DMSO priming, the DCs were washed with HI-media to 
remove all traces of DMSO before stimulation with IFN-γ/LPS. The LPS-elicited IL-
12p70 production levels were significantly lower when DMSO was removed from the 
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cells before IFN-γ/LPS stimulation compared to the cells cultured in continuous 
presence of DMSO. In fact, the increase of LPS-elicited IL-12p70 production due to 
DMSO was marginal when DMSO was removed from the culture media before LPS 
challenge. The suppression of LPS-elicited IL-10 was absent when DMSO was removed 
from the culture media. Hence, the effect of DMSO on cytokine production is reversible 
upon the removal of DMSO from the cells.  
 
4.6 DMSO primes GM-DC to favour a Th1 Type of Immune Response 
DMSO had been shown previously to be effective in regulation of IL-12 production in 
human myeloid leukemia cell lines and peripheral blood mononuclear cells (Kubin et. 
al., 1994). This study showed that pretreatment of cell lines HL-60, ML-3 and THP-1 
with DMSO for 24 hours enhances LPS-elicited IL-12 production significantly. There 
have not been many reports on the regulation of IL-12 production by DMSO. Results 
obtained for this study showed that DMSO priming of macrophages and DCs was able 
to up-regulate the LPS-elicited IL-12 production to a significant level. More focus was 
placed on the investigation of DMSO effects in regulation of IL-12 production by DCs 
because DCs are specialized APCs to initiate a response from naïve CD4
+
 T cells. IL-12 
is a heterodimeric cytokine consisting of a p40 and a p35 chain. More importantly, IL-
12 plays a critical role in regulating the balance between Th1 and Th2 immune 
responses as IL-12 is potent in inducing IFN-γ-secreting Th1 cells (Gately et. al., 1997; 
Heufler et. al., 1996). The increase of LPS-elicited IL-12 production indicates that 
DMSO could possibly skew the immune response towards a Th1 response through the 
activation of Th1 cells. Data showed that DMSO increased the IFN-γ/LPS-elicited 
production of IL-12p70, IL-12p40, and IL-23 by GM-DCs at the protein level. The 
corresponding RNA levels were also increased as shown by PCR. The three mRNA 
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transcripts of IL-12p40, IL-12p35 and IL-23p19, showed up-regulation when GM-DCs 
were primed with DMSO and subsequently stimulated with IFN-γ/LPS.  
 
One would expect to see an increase in the production of IFN-γ by CD4
+
 T cells when 
co-cultured with DMSO primed GM-DCs as DCs are potent in their IL-12p70 and IL-
12p40 production. Results of MLR indicate however, that there were no significant 
differences in IFN-γ production by the CD4
+
 T cells co-cultured with GM-DCs in the 
presence or absence of DMSO. Besides, DMSO does not affect the cytokine production 
by CD4
+
 T cells. The reason might be so that DMSO would not induce an adverse 
immune reaction in the host and hence DMSO might be considered as a potential 
adjuvant in vaccination studies. Nevertheless, It has been recently reported that high 
concentrations of DMSO do not affect T cells responses but when T cells are incubated 
with DMSO for more than 2 hr, the responses of T cells are compromised (Kloverpris et. 
al., 2010). 
 
IL-23 is another heterodimeric cytokine composed of the p40 chain and a p19 chain. IL-
23 has been suggested to be involved in the regulation of Th17 immunity and 
autoimmune disease (Mus et. al., 2010). The production of IL-23 was increased by the 
priming of DMSO for both PCR and ELISA results. This might be due to the increase 
of IL-12p40 subunit resulting in more formation of the heterodimeric cytokine. 
However, there seem to be an inhibition of IL-17 production by CD4
+
 T cells during co-
culture. Further investigations are needed to ascertain if DMSO has an inhibitory effect 
on Th17 immunity and if so, why would there be an increase in the production of IL-23 
as IL-23 is an effector for Th17 immunity. One possible reason might be the usage of 
naïve CD4+ T cells instead of memory T cells in this study. IL-17 is usually produced 
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by memory T cells. The CD4+ T cells used in this study are mainly naïve T cell and 
hence might not be as potent in IL-17 production. Besides, the IL-23 receptor is mainly 
expressed on the memory T cells (Garrett et. al., 2008). Hence, the T cells in this study 
might not be responsive to the increase in IL-23 production. Further studies using both 
memory and naïve T cells should be done for a clearer idea of DMSO regulation of 
Th17 immunity in IL-17 production.  
 
4.7 DMSO and Histone modifications 
The histone proteins of GM-DCs primed with DMSO and stimulated with IFN-γ/LPS 
were isolated for western blotting studies. This is to analyze if DMSO priming would 
result in any changes on the chromatin levels, and possibly identify if there is a 
connection between the chromatin modifications and the up-regulation of IL-12 
production. A report of mice studies suggested that DMSO was able to up-regulate 
Dnmt3a expression and at the same time alter DNA methylation profiles on a 
genomewide level (Iwatani et. al., 2006). This study was performed on mouse embryoid 
body. The authors also reported phenotypic changes as an effect of DMSO treatment on 
mouse embryonic stem cells. DMSO has been reported to be an effective histone 
deacetylase and thus has been involved in the development of an anti-cancer drug 
known as vorinostat (Marks et. al., 2007). 
 
The western blots showed that DMSO seemed to increase the di-methylation of histone 
3 on the residue lysine 9 (H3K9). Dimethylation of H3K9 is usually associated with the 
control of chromatin activities. Fission yeast experiments have shown that methylation 
of H3K4 and H3K9 are important in the maintenance of heterochromatin boundaries 
(Kouzarides, 2007). Silent heterochromatic state is usually associated with high levels 
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of methylated H3K9 and H3K27 while active heterochromatic state is associated with 
acetylated and methylated H3K4, H3K36 and H3K79. This might suggest that di-
methylation of H3K9 might be involved in the regulation of IL-12 production. GM-DCs 
primed with DMSO alone showed higher levels of di-methylated H3K27 compared to 
control GM-DCs. This further indicates that DMSO indeed is able to exert an effect at 
the chromatin level, thus affecting the transcription activity in a cell. However, further 
studies are needed to ascertain the relation between chromatin modifications and the 
regulation of IL-12 or other cytokines. 
 
4.8 Conclusion and Future work 
In conclusion, DMSO at high dosage does not appear to affect the cell survival, cell 
morphology and expression of surface markers in DCs. Neither is DMSO able to affect 
cell maturation. Nevertheless, DMSO is able to regulate the cytokine production of a 
cell, thus affecting the critical function of the cell (antigen presentation and T cell 
activation in this study) and the immune response. This has important implications 
should DMSO be approved as a drug. DMSO is a common solvent and is widely used 
for cryo-preservation due to its excellent ability in penetrating the cell membrane. The 
cellular function of a cell might be affected when DMSO is used for the cryo-
preservation though morphologically the cells would appear unchanged. It is worth 
noting that DMSO was shown to modify the dimethylation status of H3 lysine 9, 
suggesting that DMSO has the capability of inducing chromatin modifications. DMSO 
might also have the potential to function as an adjuvant since it is potent in the up-
regulation of IL-12 production while not affecting the T cell responses. However, 
further studies are needed to understand the mechanism behind the regulation of 
cytokines by DMSO. (Kieran et. al., 2004) reported that DMSO is able to regulate 
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TLR4-mediated activation of NF-γB and thus inhibit IL-8 production. Therefore, further 
studies suggested include the study of signaling mechanisms involved in the regulation 
of cytokines by DMSO, the investigation of histone regulation by DMSO and the 
potential of DMSO in eliciting a Th1 immune response in animal studies. The 
understanding of how DMSO affects the regulation of the immune responses will be 
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